Friday Satellite Symposia

Friday Satellite Symposia

Friday Satellite Symposia (FSS) are industry-supported, CME-accredited symposia that are offered the day preceding the American Society of Hematology (ASH) annual meeting. These sessions are not part of the official ASH annual meeting program and are planned solely by the organizing company.

ASH appreciates its corporate and nonprofit partners for their participation in FSS. The Society values its partnerships and the supportive role that members of this community play in an effort to provide hematologists with quality educational programs. For more information, please review the 2025 FSS guidelines or contact Kelly Cade, Grants and Satellite Symposia Manager, Consultant, at [email protected].


  • 1

    Morning Symposia

    7:00 a.m. - 10:00 a.m.
    Eastern time

    Advances in Targeting Angiogenesis and Managing Severe Anemia in Vascular Bleeding Disorders:Hereditary Hemorrhagic Telangiectasia, Von Willebrand Disease, and Beyond

    This program is supported by Pharmacosmos Therapeutics Inc.


    7:00 a.m. - 10:00 a.m. Eastern time
    OCCC - W224ABEF

    This session will be live streamed on hematology.org during the scheduled time.

    Hematologists in both community and academic practice are increasingly being called upon to use antiangiogenic treatments to treat patients with inherited and acquired vascular bleeding disorders, including hereditary hemorrhagic telangiectasia (HHT), von Willebrand disease, acquired von Willebrand syndrome, and others. This symposium will discuss the role of angiogenesis in these bleeding disorders, how to optimally manage this bleeding with anti-angiogenic agents such as bevacizumab, pomalidomide, and pazopanib, and how to properly manage the complex and difficult chronic, severe iron deficiency anemia that complicates the course of these patients. Current and future potential antiangiogenic and coagulation-based treatments will be discussed by international leaders in the field.

    Chair:

    Hanny Al-Samkari, M.D.
    Division of Hematology Oncology, Massachusetts General Hospital, Harvard Medical School, Hematology Division, Massachusetts General Hospital, Massachusetts General Hospital, Massachusetts General Hospital, Harvard Medical School

    Speakers:

    Hanny Al-Samkari, M.D.
    Division of Hematology Oncology, Massachusetts General Hospital, Harvard Medical School, Hematology Division, Massachusetts General Hospital, Massachusetts General Hospital, Massachusetts General Hospital, Harvard Medical School

    Magdalena Lewandowska, MD
    Innovative Hematology, Innovative Hematology, Indiana Hemophilia & Thrombosis Center

    Allyson Pishko, MD
    University of Pennsylvania

    Jenny Zhou, MD
    University of California, San Diego

    Contact:

    Hellen Tecle, Cure HHT
    Email: [email protected]

    Registration for In-Person Program

    Registration for Virtual Program

    Aligning Discovery With Clinical Practice: Applying Expert Consensus Guidelines To Improve Patient Outcomes in CLL/SLL

    This program is supported by AstraZeneca and Lilly. Provided by the National Comprehensive Cancer Network (NCCN) in collaboration with Clinical Care Options, LLC.


    7:00 a.m. - 10:00 a.m. Eastern time
    Virtual Symposium Only

    This session will be live streamed on hematology.org during the scheduled time.

    Join NCCN and CCO for an engaging virtual symposium focused on the real-world application of NCCN guideline–recommended therapies for patients with chronic lymphocytic leukemia (CLL). This dynamic event features expert panel discussions and interactive case challenges to explore the latest treatment strategies across frontline and relapsed/refractory settings. Gain practical insights into selecting and sequencing covalent and noncovalent BTK inhibitors, BCL2 inhibitors, CAR T-cell therapy, incorporating molecular testing, and managing adverse events to support adherence. The program also delves into emerging therapies—including BTK degraders and bispecific antibodies —offering guidance on how to integrate these innovations into clinical practice through clinical trials. Engage directly with leading experts through live Q&A and learn how to deliver personalized, evidence-aligned CLL care.

    Chair:

    Sameer A. Parikh, MD
    Division of Hematology, Mayo Clinic, Mayo Clinic

    Speakers:

    Matthew J. Cortese, MD, MPH
    Roswell Park Comprehensive Cancer Center

    Brian Hill
    Cleveland Clinic Foundation, Cleveland Clinic Cancer Institute, Taussig Cancer Center, Cleveland Clinic,, Cleveland Clinic, Cleveland Clinic Taussig Cancer Institute

    Contact:

    Melanie Moletzsky, The National Comprehensive Cancer Network
    Email: [email protected]

    Registration for Virtual Program

    Beyond Chemotherapy: Patient Voices and Expert Insights on Using Precision Therapies to Enhance Personalized Care of Follicular Lymphoma

    This program is supported by AstraZeneca, Genentech, a member of the Roche Group, Incyte Corporation, Novartis Pharmaceuticals Corporation, and Regeneron Pharmaceuticals, Inc. Provided by Clinical Care Options, LLC in partnership with the Follicular Lymphoma Foundation.


    7:00 a.m. - 10:00 a.m. Eastern time
    Hyatt - Regency Ballroom R

    This session will be live streamed on hematology.org during the scheduled time.

    Join CCO and The Follicular Lymphoma Foundation for an innovative symposium spotlighting the latest advancements in relapsed/refractory (R/R) follicular lymphoma (FL) care. This dynamic session blends global patient survey insights, expert-led case discussions, and interactive polling to explore precision, chemotherapy-free strategies. Learn how to optimize the use of bispecific antibodies, CAR T-cell therapy, and novel targeted agents such as tazemetostat, tafasitamab, and BTK inhibitors. Engage directly with expert faculty in Q&A and townhall forums as they share practical guidance on therapy selection, sequencing, safety monitoring, and real-world implementation. Stay ahead of the curve with highlights of emerging clinical trial data and future directions in FL management. This symposium will challenge your clinical perspective, deepen your understanding of the shifting FL landscape, and empower you to deliver more personalized, evidence-informed care.

    Chair:

    Laurie Sehn, MD
    BC Cancer Centre for Lymphoid Cancer and The University of British Columbia, BC Cancer Agency, BC Cancer Centre for Lymphoid Cancer and University of British Columbia, The University of British Columbia, BC Cancer

    Speakers:

    Peter Martin, FRCPC, MD, MS
    Weill Cornell Medicine, Department of Medicine, Weill Cornell Medicine,, lymphoma epidemiology of outcomes consortium (Iowa), Weill Cornell Medical College, Cornell University, Weill Cornell Medical Center

    Gilles Salles, MD, PhD
    Department of Medicine, Memorial Sloan Kettering Cancer Center, Memorial Sloan Kettering, Memorial Sloan Kettering Cancer Center, Memorial Sloan-Kettering Cancer Center, Department of Medicine, Weill Cornell Medical College, Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, Lymphoma Service, Memorial Sloan Kettering Cancer Center

    Mitchell R. Smith
    George Washington University Cancer Center, The Follicular Lymphoma Foundation

    Contact:

    Julie Dodds, The Follicular Lymphoma Foundation
    Email: [email protected]

    Registration for In-Person Program

    Registration for Virtual Program

    Consensus or Controversy? Clinical Investigators Provide Perspectives on the Current and Future Management of Patients with Acute Myeloid Leukemia

    This program is supported by educational grants from AbbVie Inc., Astellas, Daiichi Sankyo Inc., Kura Oncology, and Rigel Pharmaceuticals Inc.


    7:00 a.m. - 10:00 a.m. Eastern time
    Hyatt - Regency TUV

    This session will be live streamed on hematology.org during the scheduled time.

    This 2-hour CME-accredited activity – offered to both in-person and virtual attendees – will focus on the management of patients with acute myeloid leukemia (AML). Five clinical investigators will serve as the faculty and Dr Neil Love, RTP president, will moderate. RTP will also recruit 3 additional consulting clinical investigators who in addition to the faculty will complete a survey focused on controversial questions related to the management of AML. The responses from all 8 investigators will be graphically depicted and presented at the meeting to augment discussion and foster debate. The meeting agenda will be divided into 5 modules, each consisting of a review of survey results followed by a formal presentation of relevant research. Attendees will be able to submit questions and cases of their own, a number of which will be incorporated into the discussion. Pre-registration is advised as seating is limited.

    Chair:

    Neil Love, MD
    Research To Practice

    Speakers:

    Harry Erba, MD, PhD
    Division of Hematologic Malignancies and Cellular Therapy at Duke University, Duke Cancer Institute, Duke University Medical Center, Duke University School of Medicine, Duke University

    Amir T. Fathi, MD
    Harvard Medical School, Massachusetts General Hospital, Massachusetts General Hospital Cancer Center, Massachusetts General Hospital, Harvard Medical School

    Tara L Lin
    University of Kansas Medical Center

    Alexander Perl, MD
    University of Pennsylvania, Abramson Cancer Center of the University of Pennsylvania, Abramson Cancer Center, University of Pennsylvania, Division of Hematology-Oncology, Department of Medicine, University of Pennsylvania

    Eytan Stein, MD
    1Memorial Sloan Kettering Cancer Center, Memorial Sloan-Kettering Cancer Center, Memorial Sloan Kettering Cancer Center

    Contact:

    Sylvia Eriksen, Research To Practice
    Email: [email protected]

    Registration for In-Person Program

    Registration for Virtual Program

    Many Roads to Myeloma Remission: Making Sequential Choices With BCMA and non-BCMA Immunotherapies

    This program is supported by independent medical education grants from GSK, Johnson and Johnson and Regeneron Pharmaceuticals, Inc. This CME/MOC/EBAH/AAPA activity is provided by PVI, PeerView Institute for Medical Education and developed with our educational partner, the HealthTree Foundation for Multiple Myeloma.


    7:00 a.m. - 10:00 a.m. Eastern time
    Hyatt - Plaza Int'l HIJK

    This session will be live streamed on hematology.org and the ASH Virtual Meeting Platform during the scheduled time.


    Therapeutic innovation in relapsed/refractory multiple myeloma (RRMM) isn’t just evolving—it’s accelerating. Central to these innovations is: 1) the expansion of B-cell maturation antigen (BCMA)-targeting CAR-T therapy into earlier lines of treatment, and 2) the increasing availability of off-the-shelf immunotherapies, including antibody-drug conjugates (ADCs) and bispecific antibodies. The innovation doesn’t stop at BCMA—novel targets like GPRC5D and FcRH5 are paving new therapeutic roads for disease progression after BCMA-directed therapy. Are you prepared to utilize this expanding therapeutic arsenal to personalize treatment plans for patients with RRMM?

    Learn about optimal sequential choices with BCMA and non-BCMA immunotherapies. Using real-world patient examples, expert panelists will provide guidance on the early use of CAR-T therapy, considerations for off-the-shelf BCMA and non-BCMA immunotherapies across diverse MM settings, and insights on the clinical adoption of these therapies.

    Chair:

    Sagar Lonial, MD, FACP
    Winship Cancer Institute, Emory University Hospital, Emory University, Winship Cancer Institute, Emory University School of Medicine, Emory University of Winship Cancer Institute, Winship Cancer Institute of Emory University, Winship Cancer Institute, Emory University, Emory University School of Medicine, Emory University Winship Cancer Institute

    Speakers:

    Hans C Lee, MD
    Sarah Cannon Research Institute, Sarah Cannon Research Institute (SCRI), MD Anderson Cancer Center, The University of Texas MD Anderson Cancer Center

    Krina Patel, MD, MSc
    MD Anderson, MD Anderson Cancer Center,, University of Texas MD Anderson, M.D. Anderson Cancer Center, MD Anderson Cancer Center, The University of Texas MD Anderson Cancer Center, University of Texas M.D. Anderson Cancer Center

    Contact:

    Amanda Loeber, PVI, PeerView Institute for Medical Education
    Email: [email protected]

    Registration for In-Person Program

    Registration for Virtual Program

    MASTER MDS for Enhanced Patient Care: Modern Advances with STandard and Emerging, Risk-adapted Treatment

    This program is supported by educational grants from Bristol Myers Squibb and Geron. This CME/MOC/EBAH/AAPA activity is provided by PVI, PeerView Institute for Medical Education and developed with our educational partner, the HealthTree Foundation for Myelodysplastic Syndromes.


    7:00 a.m. - 10:00 a.m. Eastern time
    Hyatt - Plaza Int'l DEFG

    This session will be live streamed on hematology.org during the scheduled time.


    This Clinical Consults event will demonstrate how clinicians can confidently tailor myelodysplastic syndromes (MDS) care based on clinical trial data, guideline recommendations, and a comprehensive assessment of patient- and disease-related factors such as symptoms, molecular features, and care preferences. Our expert faculty will combine conversational case-based teaching, breaking evidence, and insights on the unique experiences of people living with MDS (provided by the HealthTree Foundation for Myelodysplastic Syndromes) – all with the goal of offering in-depth, patient-centric guidance.

    Chair:

    Guillermo Garcia-Manero, MD
    MD Anderson Cancer Cente, University of Texas M.D. Anderson Cancer Center, MD Anderson Cancer Center, The University of Texas MD Anderson Cancer Center, The University of Texas MD Anderson Cancer Center,, University of Texas MD Anderson Cancer Center, UT MD Anderson Cancer Center

    Speakers:

    Maria Diez-Campelo, MD, PhD
    Department of Hematology. Salamanca-IBSAL University Hospital., Hospital Universitario de Salamanca, University Hospital of Salamanca, University Hospital of Salamanca (IBSAL Cancer Center), Institute of Biomedical Research of Salamanca, University Hospital of Salamanca, Servicio de Hematología, Hospital Universitario de Salamanca, IBSAL, University Hospital of Salamanca, IBSAL, Universidad de Salamanca, Hospital Clínico Universitario de Salamanca, Hospital Universitario de Salamanca, Instituto de Investigación Biomédica de Salamanca, Hospital Universitario de Salamanca, IBSAL, Hospital Universitario de Salamanca, IBSAL, Universidad de Salamanca, University Hospital of Salamanca, Institute of Biomedical Research of Salamanca

    Sangeetha Venugopal, MD, MS
    Sylvester Comprehensive Cancer Center, University of Miami, Sylvester Comprehensive Cancer Center, University of Miami Health System, University of Miami Miller School of Medicine, University of Miami Sylvester Comprehensive Cancer Center, University of Miami

    Contact:

    Amanda Loeber, PVI, PeerView Institute for Medical Education
    Email: [email protected]

    Registration for In-Person Program

    Registration for Virtual Program

    Menin Masters for AML Care: Guidance on Integrating Menin Inhibitor Regimens & Boosting Efficacy in Challenging AML Subtypes

    This program is supported by independent educational grants from Johnson and Johnson, Kura Oncology, Inc., and Syndax. This CME/EBAH/AAPA/IPCE activity is provided by PVI, PeerView Institute for Medical Education and developed with our educational partner, the HealthTree Foundation for Acute Myeloid Leukemia.


    7:00 a.m. - 10:00 a.m. Eastern time
    OCCC - Valencia Room W415D

    This session will be live streamed on hematology.org during the scheduled time.

    Despite nearly a decade of therapeutic advances in acute myeloid leukemia (AML), challenges remain for patients with difficult-to-treat presentations, including KMT2A rearrangements or progressive NPM1-mutated disease. Menin inhibitors have emerged as a precision medicine approach to address these unmet needs, with accumulating evidence increasingly supporting their use as monotherapy and in potent combinations with standard-of-care platforms. These developments have raised questions on best practices for integrating this novel class into patient care.

    Join PeerView Live and the Health Tree Foundation at the 2025 ASH Annual Meeting and Exposition or online for expert insight on ongoing challenges in poor-prognosis AML settings and the role of menin inhibitors for KMT2Ar/NPM1m AML. Concise lectures will inform case-based discussions on the present and future of menin inhibitor–based treatment in AML, including in innovative combinations and the first-line setting.

    Chair:

    David Sallman, MD
    H. Lee Moffitt Cancer Center, Moffitt Cancer Center, H Lee Moffitt Cancer Center and Research Institute, H. Lee Moffitt Cancer and Research Institute, H Lee Moffitt Cancer Center, H. Lee Moffitt Cancer Center & Research Institute, H. Lee Moffitt Cancer Center and Research Institute

    Speakers:

    Tapan Kadia, MD
    Department of Leukemia, Division of Cancer Medicine, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Department of Leukemia, The University of Texas MD Anderson Cancer Center, The University of Texas MD Anderson Cancer Center, UT MD Anderson Cancer Center, The University of Texas MD Anderson Cancer Center,, University of Texas MD Anderson Cancer Center, MD Anderson Cancer Center, The University of Texas M.D. Anderson Cancer Center

    Dr. Emma Searle, MBChB, PhD
    The Christie NHS Foundation Trust, University of Manchester, The University of Manchester, Manchester, United Kingdom, University of Manchester, The Christie NHS Foundation Trust, The Christie NHS Foundation Trust and the University of Manchester, The University of Manchester, The Christie NHS Foundation Trust and University of Manchester, The Christie NHS Foundation Trust, Manchester, United Kingdom

    Contact:

    Amanda Loeber, PVI, PeerView Institute for Medical Education
    Email: [email protected]

    Registration for In-Person Program

    Registration for Virtual Program

    Momentum in MDS: Making Progress and Shaping a Better Future

    This program is supported by independent educational grants from Agios Pharmaceuticals, Bristol Myers Squibb, Geron Corporation, Rigel Pharmaceuticals, and Taiho Oncology, Inc. This program is provided by The Myeolodysplastic Syndromes Foundation, Inc. in partnership with AKH Inc., Advancing Knowledge in Healthcare.


    7:00 a.m. - 10:00 a.m. Eastern time
    OCCC - Tangerine Ballroom F2

    This session is in-person and does not have a virtual component. Please contact the Managing Company Contact with questions.

    Recently, significant progress has been made in understanding the biology, genetics, and pathogenesis of MDS. These advances have led to meaningful developments in diagnosis, risk-stratification, and disease management—insights that will be reflected in the new international treatment guidelines, set to be presented and published by a leading global consortium of MDS experts.

    Among the evolving topics in the field is the role of morphology in modern medicine. This issue will be explored in depth along with the implications of germline mutations in MDS patients and how this knowledge necessitates a reassessment of current clinical approaches.

    The continued need for more effective therapies has also inspired the inclusion of a dedicated session on drug development, with a specific focus on the MDS pipeline.

    The program will also feature a patient-centered discussion to bridge the gap between scientific advancements and the lived experience of those navigating MDS in real-world settings.

    Chairs:

    Moshe Mittelman, MD
    Department of Hematology, Tel Aviv Sourasky Medical Center, Tel Aviv University, Tel-Aviv Sourasky Medical Center, Tel Aviv Sourasky Medical Center, Tel Aviv Sourasky Medical Center, Tel Aviv University, Tel Aviv University Faculty of Medicine

    Valeria Santini, MD
    AOU Careggi, University of Florence, AOU Careggi-University of Florence, MDS Unit, Hematology, University of Florence, University of Florence, AOU Careggi, Azienda Ospedaliera Universitaria Careggi, University of Florence, DMSC University of Florence, AOUC, MDS Unit, Hematology, DMSC University of Florence, AOUC, University of Florence, University of Florence, AOUC, MDS Unit, Hematology, AOU Careggi, University of Florence

    Speakers:

    Rafael Bejar, MD,PhD
    UC San Diego Health, University of California San Diego, Moores Cancer Center, University of California, San Diego, Aptose Biosciences

    Rena Buckstein, MD, FRCPC
    Sunnybrook Health Sciences Centre, Odette Cancer Centre, Sunnybrook Health Sciences Centre, Sunnybrook Hospital Odette Cancer Centre

    Carmelo Gurnari, MD,PhD
    Taussig Cancer Center, Cleveland Clinic, Taussig Cancer Institute, Cleveland Clinic Foundation, Hematology, Department of Biomedicine and Prevention, University of Rome Tor Vergata, Tor Vergata University of Rome, Translational Hematology and Oncology Research Department, Taussig Cancer Center, Cleveland Clinic, University of Tor Vergata, Department of Translational Hematology and Oncology Research, Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Taussig Cancer Institute, Cleveland Clinic, Tor Vergata University, Cleveland Clinic, Department of Biomedicine and Prevention, University of Rome Tor Vergata, Department of Translational Hematology and Oncology Research, Cleveland Clinic, Tore Vergata, Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, University of Rome Tor Vergata

    Robert P Hasserjian, MD
    Massachusetts General Hospital, Harvard Medical School, Massachusetts General Hospital and Harvard Medical School

    Moshe Mittelman, MD
    Department of Hematology, Tel Aviv Sourasky Medical Center, Tel Aviv University, Tel-Aviv Sourasky Medical Center, Tel Aviv Sourasky Medical Center, Tel Aviv Sourasky Medical Center, Tel Aviv University, Tel Aviv University Faculty of Medicine

    Valeria Santini, MD
    AOU Careggi, University of Florence, AOU Careggi-University of Florence, MDS Unit, Hematology, University of Florence, University of Florence, AOU Careggi, Azienda Ospedaliera Universitaria Careggi, University of Florence, DMSC University of Florence, AOUC, MDS Unit, Hematology, DMSC University of Florence, AOUC, University of Florence, University of Florence, AOUC, MDS Unit, Hematology, AOU Careggi, University of Florence

    David Peter Steensma, MD
    Ajax Therapeutics

    Arjan Van de Loosdrecht, MD, PhD
    VU University Medical Center, Amsterdam UMC, location VUmc, CCA

    Contact:

    Lea Harrison, MDS Foundation, Inc.
    Email: [email protected]

    Registration for In-Person Program

    Registration for Virtual Program

    Moving Forward in B-ALL: Insights on Modern and Emerging Standards With Off-the-Shelf Bispecific Antibodies

    This program is supported by an independent educational grant from AstraZeneca. This CME/MOC/EBAH activity is provided by PVI, PeerView Institute for Medical Education and developed with our educational partner, the HealthTree Foundation for Acute Lymphoblastic Leukemia.


    7:00 a.m. - 10:00 a.m. Eastern time
    OCCC - Valencia Room W415BC

    This session will be live streamed on hematology.org and the ASH Virtual Meeting Platform during the scheduled time.

    Modern treatment of B-ALL reflects the ongoing evolution of precision medicine and immuno-oncology, moving beyond traditional chemotherapy and HCT to include frontline and sequential use of bispecific TCEs. Alongside established bispecifics, emerging CD19 x CD3 TCEs are poised to make inroads in R/R ALL, offering additional off-the-shelf options for use in the clinic. In light of this innovation, how can clinicians help move the field of immunotherapy forward in ALL and upgrade current treatment protocols based on the latest evidence

    In collaboration with HealthTree Foundation for ALL, this PeerView initiative, held during the ASH Annual Meeting, will provide expert perspectives on modern clinical standards in modern ALL care while preparing clinicians for future innovation with TCE strategies. Throughout the case-based workshops, the expert faculty will cover the role of TCEs, MRD monitoring, evidence supporting newer bispecifics, and practical considerations when implementing TCEs.

    Chair:

    Nicola Gökbuget, MD
    Goethe University, Goethe University Frankfurt, University Hospital, Goethe University Hospital, Department of Medicine, Hematology and Oncology, Goethe University Frankfurt, University Hospital Goethe University, University Hospital, Goethe University, University Hospital

    Speakers:

    Ibrahim Aldoss, MD
    City o Hope, City of Hope Comprehensive Cancer Center, City of Hope National Medical Center, City of Hope, City of Hope Hospital

    Nicholas J. Short, MD
    The University of Texas MD Anderson Cancer Center, UT MD Anderson Cancer Center, The University of Texas MD Anderson Cancer Center,, University of Texas MD Anderson Cancer Center, The University of Texas, MD Anderson Cancer Center, MD Anderson Cancer Center, University of Texas MD Anderson

    Contact:

    Amanda Loeber, PVI, PeerView Institute for Medical Education
    Email: [email protected]

    Registration for In-Person Program

    Registration for Virtual Program

    Off the Shelf and in the Clinic for NHL: Leveraging Bispecific Antibody Strategies in DLBCL, FL, and Beyond

    This program is supported by independent educational grants from AstraZeneca and Regeneron Pharmaceuticals, Inc. This CME/MOC/EBAH/AAPA activity is provided by PVI, PeerView Institute for Medical Education and developed with our educational partner, the HealthTree Foundation for Non-Hodgkin Lymphoma.


    7:00 a.m. - 10:00 a.m. Eastern time
    OCCC - Valencia Room W415A

    This session will be live streamed on hematology.org and the ASH Virtual Meeting Platform during the scheduled time.

    Bispecific antibodies have emerged as critical tools in the treatment arsenal for aggressive and indolent non-Hodgkin lymphoma (NHL), including diffuse large B-cell lymphoma, mantle cell lymphoma, and follicular lymphoma. These unique off-the-shelf immunotherapy options offer the opportunity to improve patient outcomes but also highlight the need for strategies to effectively integrate this transformative class of agents into patient care.

    In collaboration with HealthTree Foundation for NHL, PeerView has prepared this expert-led case-based Workshops symposium designed to model team-based care solutions for integrating bispecifics into clinical practice. Each Workshop will include high-level seminar segments covering the latest clinical evidence on modern and emerging CD20 x CD3 bispecific antibodies in diverse NHL subtypes. Throughout, the panel will address practical aspects of care such as step-up dosing, inpatient/outpatient administration, AE management, and supportive care planning. Hear the experts discuss how to bring off-the-shelf bispecifics into your clinic and offer optimal care for your patients with NHL.

    Chair:

    Prof. Dr. Max S Topp, MD
    University of Würzburg, Medical Department II, University Hospital Würzburg, Medizinische Klinik und Poliklinik II, Universitätsklinikum Würzburg, Universitätsklinikum Würzburg

    Speakers:

    Sameh Gaballa, MD
    H. Lee Moffitt Cancer Center and Research Institute, H. Lee Moffitt Cancer and Research Institute, H. Lee Moffitt Cancer Center & Research Institute, Moffit Cancer Center, H. Lee Moffitt Cancer Center, moffitt cancer center

    Deepa Jagadeesh, MD, MPH
    Cleveland Clinic Foundation, Taussig Cancer Center, Cleveland Clinic,, Cleveland Clinic, Cleveland Clinic Main Campus, Taussig Cancer Institute at Cleveland Clinic Foundation

    Contact:

    Amanda Loeber, PVI, PeerView Institute for Medical Education
    Email: [email protected]

    Registration for In-Person Program

    Registration for Virtual Program

    Paroxysmal Nocturnal Hemoglobinuria: What we have learned from the introduction of new therapies

    This program is supported by independent educational grants from AstraZeneca, Novartis, Roche, Sobi and Apellis.


    7:00 a.m. - 10:00 a.m. Eastern time
    OCCC - Tangerine Ballroom F1

    This session is in-person and does not have a virtual component. Please contact the Managing Company Contact with questions.

    The 2025 Symposium will address the impact of diagnostic and therapeutic advances over the past 143 years on recent advances in the management of patients with this rare but fascinating acquired genetic disorder involving hematopoietic stem cells. The program combines a historical perspective along with recent scientific data on the impact of therapies targeting several complement factors, proximal, distal; and both. The program will discuss the new scenario of  of broad treatment options, as well as ongoing scientific projects of the IPIG, such as the work underway to modernize diagnostic and therapeutic guidelines of novel guidelines and the development of an International, academic disease registry. The availability of appropriate diagnostics and therapies in different parts of the world.

    Chairs:

    Morag Griffin, FRCPath, MBChB, MRCP
    Leeds Teaching Hospital NHS, St James's Hospital, NHS Teaching Hospitals, St James's University Hospital, Leeds Teaching Hospitals NHS Trust, St James University Hospital, St James’s University Hospital, St. James University Hospital

    Phillip Scheinberg, MD
    Hospital A Beneficência Portuguesa de São Paulo, Hospital A Beneficência Portuguesa, Hospital A Beneficencia Portuguesa

    David Araten, MD
    NYU Langone, NYU Grossman School of Medicine, NYU Cancer Institute

    Speakers:

    Louise Marianne Arnold, ACP, MSc
    Leeds Teaching Hospital NHS, St James University Hospital, St James's University Hospital

    Camilla Frieri
    U.O.C Ematologia e Terapie cellulari avanzate, AORN San Giuseppe Moscati, AORN S. Giuseppe Moscati, AORN San Giuseppe Moscati Avellino

    Xiaojun Huang
    Peking University People’s Hospital, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University People’s Hospital, Peking University Institute of Hematology, Beijing, China. National Clinical Research Center for Hematologic Disease, Beijing, China. Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, China., Peking University People’s Hospital, Peking University Institute of Hematology, Beijing, China. National Clinical Research Center for Hematologic Disease, Beijing, China. Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Peking University People’s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Peking University People’s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Collaborative Innovation Center of Hematology China, Peking University, Peking-Tsinghua Center for Life Sciences, Research Unit of Key Technique for Diagnosis and Treatments of Hematologic Malignancies, Chinese Academy of Medical Sciences, 2019RU029, Beijing, China, 1. Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China, National Clinical Research Center for Hematologic Disease, Peking University Institute of Hematology, Peking University People's Hospital, Peking-Tsinghua Center for Life Sciences, Beijing 100044, China., Peking University People's Hospital, Peking University People’s Hospital

    Bhavisha Patel
    National Heart, Lung and Blood Institute, NIH, NHLBI, NIH, Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA, National Heart, Lung, and Blood Institute/NIH, National institutes of Health, Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health

    Daniel Payne
    James Cook University Hospital, Leeds Teaching Hospital NHS

    Regis Peffault De Latour, MD
    Assistance Publique des Hôpitaux de Paris, Hôpital Saint-Louis, Assistance Publique Hôpitaux de Paris, Université Paris Cité, Hematology and Transplantation Unit, Hôpital Saint Louis, AP-HP, Leukemia Institute Paris Saint-Louis, Saint-Louis Hospital, BMT Unit, Paris, France, St. Louis Hopital, The Severe Aplastic Anemia Working Party of the European Society for Blood and Marrow Transplantation, BMT Unit, Hopital Saint-Louis, EBMT, Hôpital Saint-Louis, Saint-Louis Hospital, Saint-Louis Hospital, BMT Unit, BMT Unit, French Reference Center for Aplastic Anemia and PNH, Hôpital Saint-Louis, Université Paris Cité, Paris, France, European Group for Blood and Marrow Transplantation (EBMT), French Reference Center for Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria, Hôpital Saint Louis, Hôpital Saint-Louis, APHP, Université de Paris Cité, Université Paris Cité, St Louis University Hospital

    Antonio M. Risitano, MD, PhD
    AORN Moscati, 20University of Naples, 7A.O.R.N. 'SAN.G MOSCATI', European Group for Blood and Marrow Transplantation (EBMT), University of Naples Federico II, AORN San G. Moscati, AORN San Giuseppe Moscati Avellino, EBMT, Federico II University of Naples, International PNH Interest Group, AORN S. Giuseppe Moscati, The Severe Aplastic Anemia Working Party of the European Society for Blood and Marrow Transplantation

    Jeff Szer, BMedSc, MB, BS
    Peter MacCallum Cancer Centre, The Royal Melbourne Hospital, AORN San Giuseppe Moscati Avellino

    Contact:

    Dawn McKnight, AORN San Giuseppe Moscati Avellino
    Email: [email protected]

    Registration for In-Person Program

    Pathways to Personalized Remission in CLL: Leveraging Targeted Standards & Next-Gen Advances for Upfront and Sequential Care

    This program is supported by independent educational grants from AstraZeneca, BeOne Medicines, and Lilly. This CME/MOC/EBAH/AAPA/IPCE activity is provided by PVI, PeerView Institute for Medical Education and developed with our educational partner, CLL Society.


    7:00 a.m. - 10:00 a.m. Eastern time
    Hyatt - Orlando Ballroom

    This session will be live streamed on hematology.org and the ASH Virtual Meeting Platform during the scheduled time.

    The modern CLL care pathway now centers on the continuous use of covalent BTK inhibitors (BTKi) and time-limited BCL2 inhibitor (BCL2i) regimens. New time-limited BTKi-BCL2i combinations have emerged to offer innovative standards for treatment-naïve patients, while in the relapsed/refractory setting, non-covalent BTKis, CAR-T cell therapy, and next-generation agents have emerged as standards of care in their own right or in potentially novel ways (such as with BTK degraders) to attack CLL.

    In collaboration with CLL Society, this PeerView expert-led activity during the 67th ASH Annual Meeting and Exposition will cover modern CLL pathways to remission through a series of interactive, case-based workshops focused on real-world challenges in CLL care. Throughout, the panelists will model team-based strategies for improving outcomes with continuous or time-limited therapy in frontline settings, while providing insights on the evidence- and guideline-based use of targeted therapy for sequential care in relapsed/refractory CLL.

    Chair:

    John Gribben, MD, DSc, FRCP, FMedSci, FRCPath
    Barts Cancer Institute, Barts and The London School of Medicine, Queen Mary, University of London, Queen Mary University of London, Barts Cancer Institute, Barts Cancer Institute, Queen Mary University of London

    Speakers:

    Nicole Lamanna, MD
    Herbert Irving Comprehensive Cancer Center New York-Presbyterian/Columbia University Medical Center, Herbert Irving Comprehensive Cancer Center, Columbia University

    Meghan C. Thompson, MD
    CLL Program, Leukemia Service, Division of Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, Memorial Sloan Kettering Cancer Center

    William G. Wierda, MD, PhD
    University of Texas MD Anderson Cancer Center, The University of Texas MD Anderson Cancer Center, MD Anderson Cancer Center

    Contact:

    Amanda Loeber, PVI, PeerView Institute for Medical Education
    Email: [email protected]

    Registration for In-Person Program

    Registration for Virtual Program

    Reaching Clinical Trial Excellence: Practical Strategies for Achieving Generalizable and Transportable Data

    This program is supported by Indy Hematology Education Inc.


    7:00 a.m. - 10:00 a.m. Eastern time
    OCCC - W224CDGH

    This session is in-person and does not have a virtual component. Please contact the Managing Company Contact with questions.

    This workshop will bring together experts in clinical research, policy, biostatistics, and patient advocacy to address the persistent underrepresentation of diverse populations in clinical trials. Through a multi-session format, the event will explore systemic, provider-level, and patient-level barriers to equitable trial access and participation.

    The first session will focus on structural solutions, highlighting how governance, industry partnerships, legal frameworks, and editorial policies can be aligned to drive inclusive research design and dissemination. Participants will gain insight into actionable strategies to embed equity at the institutional level.

    The second session will center on the provider’s role in promoting representation. Speakers will examine how to educate, recruit, and retain investigators committed to equitable research, as well as how biostatistical tools can identify and correct bias within trial design and execution.

    Finally, the third session will explore patient-level barriers to trial access, including restrictive eligibility criteria and historical mistrust. Presenters will share approaches to designing more inclusive protocols, building trust with underserved communities, and elevating the role of patient advocates.

    Together, these sessions will provide a comprehensive framework for creating more representative, ethical, and effective clinical research that leads to better outcomes for all populations.

    Chairs:

    Andrew Hantel, MD, MPH
    Assistant Professor of Medicine; Harvard Medical School, Dana Farber Cancer Institute, Dana-Farber Cancer Institute, Harvard Medical School

    Karen Winkfield
    Vanderbilt University Medical Center

    Speakers:

    Maya Nicole Birhiray, M.S.
    Indy Hematology Education Inc, Indiana University School of Medicine, Medical Student; Indiana University School of Medicine

    Carmen Guerra, MSCE, FACP
    University of Pennsylvania: Perelman School of Medicine

    Catherine Lai, MD, MPH
    University of Pennsylvania, Abramson Cancer Center, University of Pennsylvania, Associate Professor of Clinical Medicine and Physician Leader of the Leukemia Clinical Research Unit; University of Pennsylvania’s Perelman Center for Advanced Medicine, Hospital of the University of Pennsylvania

    Medha Makhlouf, JD
    Penn State Dickinson Law

    Alan Mast, MD, Ph.D.
    Versiti Blood Research Institute

    Chadi Nabhan, MBA, FACP
    Ryght Inc., University of South Carolina, Ryght AI, Inc

    Sam Ranger, M.S.
    Indy Hematology Education Inc., Indy Hematology Education Inc

    Nikhil Thaker, MHA, MBA, PMP, CMQ, FABS, DABR, DABPM
    AI in Precision Oncology

    Karriem Watson, DHSc, MS, MPH
    Mile Square Health Center

    Contact:

    Sam Ranger, Indy Hematology Education Inc., Indy Hematology Education Inc
    Email: [email protected]

    Registration for In-Person Program

    Redrawing Frontlines in MCL: The Upfront Expansion of BTKi Options & Modern Clinical Decision-making in Newly Diagnosed Disease

    This program is supported by an independent educational grant from AstraZeneca. This CME/MOC/EBAH/AAPA activity is provided by PVI, PeerView Institute for Medical Education and developed with our educational partner, the HealthTree Foundation for Mantle Cell Lymphoma.


    7:00 a.m. - 10:00 a.m. Eastern time
    Hyatt - Regency Ballroom S

    This session will be live streamed on hematology.org and the ASH Virtual Meeting Platform during the scheduled time.

    Bruton’s tyrosine kinase inhibitors (BTKi) are reshaping mantle cell lymphoma (MCL) treatment. This began with the second-line use of BTKi following progression on chemoimmunotherapy (CIT) and now includes the 1L use of BTKi regimens based on evidence that combinations with CIT can improve outcomes. Simultaneously, BTKi-based chemo-free regimens have been effective in frail, newly diagnosed patients, signaling another potential change in 1L treatment. This introduces new opportunities for BTKi-based frontline combinations to enhance outcomes and quality of life.

    In collaboration with HealthTree Foundation for Mantle Cell Lymphoma, PeerView’s Clinical Consults symposium will link case-based teaching with lectures to demonstrate how the latest evidence on 1L BTKi platforms is impacting decision-making for different MCL presentations and patient cohorts. Experts will provide insights on using BTKi-CIT regimens in transplant and non-transplant settings and guidance on using BTKi options as part of a chemo-free strategy.

    Chair:

    Martin Dreyling, MD, PhD
    Ludwig-Maximilian-University (LMU) Hospital, Munich, Department of Internal Medicine III. German Cancer Consortium (DKTK), Munich, and German Cancer Research Center (DKFZ), Heidelberg, Germany., Ludwig-Maximilian-University Munich, Medizinische Klinik III, Klinikum der Universität, LMU München, Department of Medicine III, University Hospital, Ludwig-Maximilian-University, Klinikum der Universitat LMU Muchen, LMU Hospital Munich, LMU University Hospital, Ludwig-Maximilians-University Hospital, Department of Medicine III, University Hospital, LMU Munich, Ludwig Maximilian University Hospital of Munich, University Hospital, LMU

    Speakers:

    Kami Maddocks, MD
    The Ohio State University Comprehensive Cancer Center, The Ohio State University Comprehensive Cancer Center – James Cancer Hospital, Division of Hematology, Department of Internal Medicine, The Ohio State University, Ohio State University Comprehensive Cancer Center, The Ohio State University, The Ohio State University Medical Center

    Christine Ryan, MD
    Dana Farber Cancer Institute, Harvard Medical School, Dana-Farber Cancer Institute, Dana-Farber Cancer Institute, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School

    Contact:

    Amanda Loeber, PVI, PeerView Institute for Medical Education
    Email: [email protected]

    Registration for In-Person Program

    Registration for Virtual Program

    Rising to the Graft-vs-Host Disease Challenge: Progress in Treatment and Post-HCT Outcomes Across Hematologic Cancers

    This program is supported by independent educational grants from Incyte Corporation, Mesoblast Inc, Orca Bio, and Sanofi US. This CME/MOC/EBAH/AAPA activity is provided by PVI, PeerView Institute for Medical Education and developed with our educational partner, the Blood and Marrow Transplant Information Network.


    7:00 a.m. - 10:00 a.m. Eastern time
    OCCC - W331

    This session will be live streamed on hematology.org and the ASH Virtual Meeting Platform during the scheduled time.

    This Clinical Consults activity, developed in partnership with BMT InfoNet, will provide learners with a comprehensive overview of innovative strategies for managing graft-vs-host disease (GVHD). Our expert faculty panel will explore new targeted and cellular-based therapies that aim to reduce nonrelapse mortality while preserving the graft-versus-tumor effect. Through real-world scenarios and expert-led discussions, attendees will gain insights on modern targeted options (such as JAK and ROCK inhibitors), as well as the emerging role of precision T-cell and other cell-based therapies. During the event, experts will also highlight resources that can be used to engage with patients preparing for allogeneic hematopoietic cell transplantation who are at risk for GVHD. Be sure you are equipped to rise to the GVHD challenge.

    Chair:

    Zachariah Defilipp, MD
    Massachusetts General Hospital, Harvard Medical School, Massachusetts General Hospital

    Speakers:

    Betty K. Hamilton
    Cleveland Clinic Taussig Cancer Institute, Cleveland Clinic, Cleveland Clinic Foundation

    Amandeep Salhotra
    City of Hope National Medical Center

    Contact:

    Amanda Loeber, PVI, PeerView Institute for Medical Education
    Email: [email protected]

    Registration for In-Person Program

    Registration for Virtual Program

    Steady Progress in Multiple Myeloma: Applying New Data and Updated Guidelines Throughout Treatment

    This program is supported by AbbVie and GSK, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC and Karyopharm Therapeutics. Provided by the National Comprehensive Cancer Network (NCCN) in collaboration with Clinical Care Options, LLC.


    7:00 a.m. - 10:00 a.m. Eastern time
    Hyatt - Regency Ballroom OPQ

    This session will be live streamed on hematology.org during the scheduled time.

    Join CCO for an engaging symposium focused on the real-world application of NCCN guideline–recommended therapies for patients with multiple myeloma (MM). This dynamic event combines expert panel discussions and interactive case challenges to explore evolving treatment strategies across the MM continuum—from smoldering and newly diagnosed disease to relapsed/refractory settings. Gain practical insights into selecting and sequencing therapies such as triplet and quadruplet regimens, bispecific antibodies, and CAR T-cell products, while managing associated toxicities and coordinating care across practice settings. The program also addresses disparities in access to care and strategies to promote equitable treatment delivery. Engage directly with leading MM experts through live polling and Q&A sessions, apply the latest evidence to real-world cases, and preview key NCCN updates and ASH 2025 data. This symposium will deepen your understanding of guideline-aligned MM care, challenge your clinical decision-making, and empower you to optimize outcomes for diverse patient populations.

    Chair:

    Thomas Martin, MD
    Helen Diller Family Comprehensive Cancer Center, University of California at San Francisco, UCSF, University of California San Francisco, University of California, San Francisco

    Speakers:

    Carol Huff, MD
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

    Adriana Rossi
    Tisch Cancer Institute

    Contact:

    Melanie Moletzsky, The National Comprehensive Cancer Network
    Email: [email protected]

    Registration for In-Person Program

    Registration for Virtual Program

  • 2

    Early Afternoon Symposia

    11:00 a.m. - 2:00 p.m.
    Eastern time

    ‘Four’ Every Patient: Maximizing Outcomes in Newly Diagnosed Multiple Myeloma Care with Anti-CD38 Monoclonal Antibody-Based Quadruplet Therapies

    This program is supported by an educational grant from Sanofi. Provided by Answers in CME.


    11:00 a.m. - 2:00 p.m. Eastern time
    OCCC - Valencia Room W415D

    This session will be live streamed on hematology.org during the scheduled time.

    Quadruplet regimens powered by anti-CD38 antibodies have transformed the treatment landscape in newly diagnosed multiple myeloma. Are you confident you’re using these game-changing therapies to their full potential? This interactive 60-minute symposium brings you face-to-face with two leading multiple myeloma experts—Paul Richardson, MD, and Caitlin Costello, MD—who will decode the latest phase 3 trial data, review strategies for tackling side effects, and offer insights on personalizing therapy. Participate in the live Q&A to challenge the faculty with your real-world patient scenarios and sharpen your insight into NDMM therapies. Don’t just keep up with the cutting edge—be part of it. Claim your seat at the next evolution in multiple myeloma care!

    Speakers:

    Caitlin Costello, MD
    Moores Cancer Center at University of California San Diego, Moores Cancer Center, University of California San Diego, UC San Diego, Division of Blood and Marrow Transplantation, University of California San Diego, University of California, San Diego

    Paul G. Richardson, MD
    Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Dana Farber Cancer Institute, Dana-Farber Cancer Institute, Dana-Farber Cancer Institute, Harvard Medical School, Harvard Medical School, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute

    Contact:

    Kaitlyn Hoster Jr, Answers in CME
    Email: [email protected]

    Registration for In-Person Program

    Registration for Virtual Program

    A Master Class in CP-CML: New Agents, Treatment Goals, and Clinical Challenges

    This program is supported by Novartis Pharmaceuticals Corporation. Provided by Clinical Care Options, LLC.


    11:00 a.m. - 2:00 p.m. Eastern time
    Hyatt - Regency Ballroom R

    This session will be live streamed on hematology.org during the scheduled time.

    Join CCO for this engaging symposium reviewing the latest advancements in chronic phase chronic myeloid leukemia (CP-CML) management. This activity will feature experts discussing cases illustrating clinical applications of the latest data and strategies to optimize the diagnosis, treatment, and management of CP-CML. Engage directly with leading experts through multiple discussion sessions, where you can present your questions and real-world cases for personalized guidance. Navigate the evolving evidence for individualized frontline CP-CML treatment, optimize response monitoring strategies, and gain insights into current recommendations for managing treatment intolerance and failure. This symposium promises to enrich your understanding of CP-CML, challenge your clinical acumen, and empower you to apply the latest evidence in your practice. Contribute to thought-provoking dialogues on CP-CML, shaping the discourse and enhancing collective expertise in this critical field.

    Chair:

    Jerald Radich, MD
    Fred Hutch Cancer Center, University of Washington, Fred Hutchinson Cancer Center

    Speakers:

    Neil P. Shah
    University of California

    B. Douglas Smith, MD
    Johns Hopkins, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Hospital, Johns Hopkins University School of Medicine, John Hopkins University, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University

    Contact:

    Ishana Fleurant, Clinical Care Options, LLC.
    Email: [email protected]

    Registration for In-Person Program

    Registration for Virtual Program

    Accelerating Evidence Into Practice: Leveraging QI-Driven Insights and Practical Tools to Integrate Bispecific Antibodies Into Care for Patients With R/R DLBCL and FL

    This program is supported by PRIME Education. There is no fee to participate. This activity is supported by an educational grant from Genmab US, Inc.


    11:00 a.m. - 2:00 p.m. Eastern time
    OCCC - W331

    This session will be live streamed on hematology.org during the scheduled time.

    Join lymphoma experts as they take a deep dive into the latest clinical evidence and practical considerations for evidence-based integration of bispecific antibodies (bsAbs) into treatment plans for patients with DLBCL and FL. Featuring patient testimonials to provide patient perspectives on receiving bsAbs and discuss treatment preferences, the expert faculty will guide the audience through nuances for navigating step-up dosing schedules and individualized treatment decision-making while reviewing the latest clinical evidence and guideline recommendations. Learners will have access to established resources from prior initiatives with bsAb therapy in DLBCL/FL to support optimal administration and management. Additionally, Throughout the program, faculty will engage the onsite and virtual attendees through gamified interactive polling and participate in a live Q&A. Altogether, this satellite symposium will harness real-world testimonials and clinic-focused resources to deepen the impact of the education and support providers in enhancing the care and delivery of bsAbs for DLBCL and FL.

    Chair:

    Paolo Strati, MD
    Dr. Merryman and Dr. Strati share co-senior authorship, MD Anderson Cancer Center, Department of Lymphoma and Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, University of Texas MD Anderson Cancer Center, The University of Texas MD Anderson Cancer Center

    Speaker:

    Caron Jacobson, MD, MMSc
    Dana Faber Cancer Institute, Dana Farber Cancer Institute, Dana-Farber Cancer Institute

    Contact:

    Eryn Litvinas, PRIME Education
    Email: [email protected]

    Registration for In-Person Program

    Registration for Virtual Program

    Advancing Hemophilia Care—Uniting Expert Insights and Community Voices to Shape the Future of Non-Factor Replacement Therapy

    This program is supported by Novo Nordisk. Provided by Clinical Care Options, LLC.


    11:00 a.m. - 2:00 p.m. Eastern time
    Hyatt - Orlando Ballroom

    This session will be live streamed on hematology.org during the scheduled time.

    Join CCO for an engaging symposium focused on advancing hemophilia care through non-factor replacement therapies. This dynamic event combines expert panel discussions, real-world case challenges, and insights from patients and community HCPs to explore the latest data on novel therapies including fitusiran, concizumab, marstacimab, and Mim8. Through interactive polling and audience Q&A, attendees will gain practical guidance on integrating these therapies into personalized care strategies for patients with moderate to severe hemophilia A and B. Discover how to navigate evolving safety profiles, improve joint health outcomes, and tailor treatment based on patient needs and preferences. This symposium offers a comprehensive view of current challenges, cutting-edge solutions, and future directions in hemophilia management, equipping you with actionable insights to improve clinical practice.

    Chair:

    Steven Pipe, MD
    Hemophilia and Coagulation Disorders Program, University of Michigan

    Speakers:

    Stacy Croteau, MD
    Harvard Medical School

    Kristin Maher
    University of Washington

    Contact:

    Ishana Fleurant, Clinical Care Options, LLC.
    Email: [email protected]

    Registration for In-Person Program

    Registration for Virtual Program

    Advancing Outcomes in Lymphoma Care: A Master Class on Integrating the CAR T-Cell Therapies into Clinical Practice

    This program is supported by Bristol Myers Squibb and Kite Pharma, Inc. Provided by Clinical Care Options, LLC.


    11:00 a.m. - 2:00 p.m. Eastern time
    Hyatt - Regency Ballroom OPQ

    This session will be live streamed on hematology.org during the scheduled time.

    Join CCO for an engaging symposium exploring the latest advancements in CAR T-cell therapy for relapsed/refractory (R/R) lymphomas. This dynamic event features expert-led discussions, real-world case challenges, and interactive polling to examine the expanding role of CAR T-cell therapies across B-cell lymphoma subtypes. Gain practical insights into patient selection, referral pathways, and coordination of care, along with strategies to manage acute and chronic toxicities such as CRS and ICANS. Learn how to educate patients and caregivers, implement survivorship planning, and optimize long-term outcomes. The symposium also highlights next-generation CAR T-cell innovations, including off-the-shelf products and combination strategies. Engage directly with faculty during live Q&A sessions, apply knowledge through interactive cases, and leave equipped to enhance care for patients receiving CAR T-cell therapy.

    Chair:

    Stephen Ansell, MD, PhD
    Mayo Clinic Comprehensive Cancer Center, Mayo Clinic

    Speakers:

    Jeremy Abramson, MD
    Massachusetts General Hospital, Massachusetts General Hospital, Harvard Medical School, Center for Lymphoma, Massachusetts General Hospital Cancer Center, Massachusetts General Hospital Cancer Center, Massachusetts General Hospital Cancer Center, Harvard Medical School, Harvard Medical School

    Michael D. Jain
    H. Lee Moffitt Cancer and Research Institute, H. Lee Moffitt Cancer Center & Research Institute, H. Lee Moffitt Cancer Center, Moffitt Cancer Center, H Lee Moffitt Cancer Center, Lee Moffitt Cancer Center, Moffit Cancer Center & Research Institute

    Patrick Connor Johnson, MD
    Cellular Immunotherapy Program, Massachusetts General Hospital Cancer Center, Harvard Medical School, Department of Medicine, Hematology, and Oncology Division, Massachusetts General Hospital Cancer Center, Harvard Medical School, Harvard Medical School, Massachusetts General Hospital, Massachusetts General Hospital Cancer Center, Massachusetts General Hospital Cancer Center, Harvard Medical School, Division of Hematology and Oncology, Massachusetts General Hospital, Harvard Medical School

    David Maloney
    University of Washington

    Contact:

    Ishana Fleurant, Clinical Care Options, LLC.
    Email: [email protected]

    Registration for In-Person Program

    Registration for Virtual Program

    Cases & Conversations™: Real-World Insights on Advances in the Management of Myeloproliferative Neoplasms: How the Experts Apply the Latest Developments to Clinical Practice

    This program is supported by Geron Corporation, Incyte Corporation, PharmaEssentia, and Takeda.


    11:00 a.m. - 2:00 p.m. Eastern time
    OCCC - W224ABEF

    This session will be live streamed on hematology.org during the scheduled time.

    The live portion of this curriculum will be presented as a 2.5-hour Friday Satellite Symposium (FSS) held prior to the 2025 ASH Annual Meeting. This satellite program will bring together 4 clinical experts to review the latest data regarding the management of MPNs, with short didactic presentations supplemented by panel discussions of challenging case scenarios. To further enhance the integration of recent data into practice, the program will feature an interactive question-and-answer session between the faculty and attendees to emphasize areas of educational need, highlight areas of debate, and illustrate the application of new data in defined clinical situations.

    Chair:

    Naveen Pemmaraju, MD
    Executive Director, MDACC Network, The University of Texas MD Anderson Cancer Center, University of Texas MD Anderson Cancer Center, The University of Texas MD Anderson Cancer Center, Department of Leukemia, The University of Texas MD Anderson Cancer Center, MD Anderson Cancer Center, The University of Texas MD Anderson Cancer Center,, University of Texas, MD Anderson Cancer Center, UT MD Anderson Cancer Center

    Speaker:

    Angela Fleischman, MD, PhD
    University of California, Irvine, School of Medicine, University of California, Irvine, UC Irvine

    Contact:

    Elijah Anseaume, Physicians’ Education Resource®, LLC (PER)
    Email: [email protected]

    Registration for In-Person Program

    Registration for Virtual Program

    Cases from the Community: Investigators Discuss Available Research Guiding the Selection of Therapy for Patients with Chronic Lymphocytic Leukemia

    This program is supported by educational grants from Abbvie Inc., AstraZeneca Pharmaceuticals LP, BeOne, Bristol Myers Squibb, and Lilly.


    11:00 a.m. - 2:00 p.m. Eastern time
    Hyatt - Regency TUV

    This session will be live streamed on hematology.org during the scheduled time.

    This 2-hour CME-accredited activity – offered to both in-person and virtual attendees – will focus on the management of patients with chronic lymphocytic leukemia (CLL). Four clinical investigators will serve as the faculty and Dr Neil Love, RTP president, will moderate. Prior to the meeting, Research To Practice (RTP) will video record interviews with 3 general medical oncologists/hematologists (GMOs) who will present challenging CLL cases from their practices. To begin each of the 4 meeting modules, excerpts from the GMO interviews will be broadcast and the panelists will discuss the optimal management of the patients presented. 1 faculty member will then deliver a formal presentation reviewing available research related to the cases. Attendees will be able to submit questions and cases of their own, a number of which will be incorporated into the discussion. Pre-registration is advised as seating is limited.

    Chair:

    Neil Love, MD
    Research To Practice

    Speakers:

    Matthew S Davids, MD
    Broad Institute of MIT and Harvard, Dana-Farber Cancer Institute and Harvard Medical School, Department of Medicine, Harvard Medical School, Dana Farber Cancer Institute, Dana-Farber Cancer Institute, Dana-Farber Cancer Institute, Harvard Medical School, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School

    Bita Fakhri, MD, MPH
    Stanford University School of Medicine, Stanford Cancer Institute, Stanford University, Division of Hematology at Stanford University School of Medicine, Stanford University

    Constantine S. Tam, MD,MBBS
    Alfred Health and Monash University, Alfred Hospital and Monash University, Australian Centre for Blood Diseases, Monash University, Alfred Health & Monash University, Alfred Hospital, Monash University

    Jennifer A. Woyach, MD
    Ohio State University Comprehensive Cancer Center, The Ohio State University Medical Center, The Ohio State University Comprehensive Cancer Center, The Ohio State University James Comprehensive Cancer Center, The Ohio State University

    Contact:

    Sylvia Eriksen, Research To Practice
    Email: [email protected]

    Registration for In-Person Program

    Registration for Virtual Program

    From Indolent to Aggressive: Case-Based Strategies Across the Spectrum of Systemic Mastocytosis

    This program is supported by an independent educational grant from Blueprint Medicines Corporation and provided by Integritas Communications.


    11:00 a.m. - 2:00 p.m. Eastern time
    OCCC - W224CDGH

    This session will be live streamed on hematology.org during the scheduled time.

    Systemic mastocytosis (SM) is a complex and often misdiagnosed condition that can affect multiple organ systems and cause symptoms ranging from anaphylaxis to bone pain and gastrointestinal distress. This interactive Case-in-Point™ CME symposium will feature real-world case discussions, audience polling, and expert insights to help clinicians navigate the challenges of diagnosing and managing both nonadvanced and advanced SM. Expert faculty will review updated diagnostic criteria, emerging and FDA-approved treatment strategies, and provide practical guidance on monitoring treatment response, addressing persistent symptoms, and engaging patients in shared decision-making. Whether you are new to SM care or looking to refine your approach, this session will enhance your confidence and equip you with practical strategies to optimize care for patients across the SM spectrum.

    Pre-registration is advised as seating is limited.

    Speakers:

    Brian J. Chernak, MD
    Leukemia Specialist, Memorial Sloan Kettering Cancer Center

    Matthew P. Giannetti
    Division of Allergy and Clinical Immunology, Brigham and Women’s Hospital, Associate Director, Brigham and Women’s Hospital Mastocytosis Center

    Tsewang Tashi, MD
    Associate Professor, Division of Hematology & Hematologic Malignancies, University of Utah, Huntsman Cancer Institute, Huntsman Cancer?Institute, University of Utah

    Contact:

    Shannon Stevenson, Integritas, Integritas Communications
    Email: [email protected]

    Registration for In-Person Program

    Registration for Virtual Program

    Medical Crossfire®: Advances in ALL Management Across the Patient Spectrum: Integrating Innovation and Precision Care

    This program is supported by Servier, Jazz, Amgen, and Autolus Inc.


    11:00 a.m. - 2:00 p.m. Eastern time
    OCCC - Tangerine Ballroom F1

    This session will be live streamed on hematology.org during the scheduled time.

    The live portion of this curriculum will be presented as a 2.5-hour Friday Satellite Symposium (FSS) held prior to the 2025 ASH Annual Meeting.

    This satellite program will bring together four clinical experts to review the latest data regarding the management of patients with ALL, with short didactic presentations supplemented by panel discussions of challenging case scenarios.

    The program will bring to the patient voice to the forefront, with panel discussions between the clinical experts and a patient advocate to review practical measures bridge disparities in the treatment of ALL.

    Chair:

    Elias Jabbour
    University of Texas MD Anderson Cancer Center, The University of Texas MD Anderson Cancer Center, The University of Texas MD Anderson Cancer Center,, UT MD Anderson Cancer Center, MD Anderson, MD Anderson Cancer Center, University of Texas MD Anderson

    Speakers:

    Hagop Kantarjian, MD
    MD Anderson Cancer Center, The University of Texas MD Anderson Cancer Center, Department of Leukemia, The University of Texas MD Anderson Cancer Center, University of Texas MD Anderson Cancer Center

    Aaron C. Logan, MD, PhD
    Hematology, Blood and Marrow Transplantation, and Cellular Therapy Program, University of California at San Francisco, Hematology, Blood and Marrow Transplantation, and Cellular Therapy Program, University of California San Francisco, University of California, San Francisco, UCSF

    Rob Pieters, MD, PhD, MSc
    Princess Máxima Center for Pediatric Oncology

    Claire Roddie, MD, PhD
    University College London Cancer Institute, University College London Hospitals NHS Foundation Trust, University College London Hospital, University College London, University College London (UCL) Hospitals

    Contact:

    Elijah Anseaume, Physicians’ Education Resource®, LLC (PER)
    Email: [email protected]

    Registration for In-Person Program

    Registration for Virtual Program

    Medical Crossfire®: Experts Debate the Hottest Topics in AML – FLT3, IDH1/2, KMT2Ar, NPM1, Secondary AML, Maintenance, Novel Combinations, and Emerging Therapies

    This program is supported by Kura Oncology, Inc., Rigel Pharmaceuticals, Inc. and Taiho Oncology Inc.


    11:00 a.m. - 2:00 p.m. Eastern time
    OCCC - Tangerine Ballroom F2

    This session will be live streamed on hematology.org during the scheduled time.

    CME - Certified Hybrid Satellite Symposium    :

    The live portion of this curriculum will be presented as a 3.0-hour Friday Satellite Symposium (FSS) held prior to the 2025 ASH Annual Meeting.

    This satellite program will bring together four clinical experts to review the latest data regarding the management of AML, with short didactic presentations supplemented by panel discussions of challenging case scenarios.

    The program will bring to the patient voice to the forefront, with panel discussions between the clinical experts and a patient advocate to review practical measures bridge disparities in the treatment of AML.

    To further enhance the integration of recent data into practice, the program will feature an interactive polling and question-and-answer sessions between the faculty and attendees to emphasize areas of educational need, highlight areas of debate, and illustrate the application of new data in defined clinical situations.

    Chair:

    Naval Daver, MD
    Department of Leukemia, The University of Texas MD Anderson Cancer Center, MD Anderson Cancer Center, The University of Texas MD Anderson Cancer Center, The University of Texas, MD Anderson Cancer Center, The University of Texas MD Anderson Cancer Center,, U.T. MD Anderson Cancer Center, Houston, University of Texas MD Anderson Cancer Center, University of Texas, MD Anderson Cancer Center, UT MD Anderson Cancer Center

    Speakers:

    Daniel Pollyea, MD
    Clinical Director of Leukemia Services, University of Colorado, Division of Hematology, School of Medicine, University of Colorado, University of Colorado, University of Colorado School of Medicine, Division of Hematology, University of Colorado

    Gail J Roboz
    Cornell University Sandra and Edward Meyer Cancer Center, Weill Cornell Medical College, Weill Cornell Medical Center, Weill Cornell Medical College and the New York-Presbyterian Hospital, Weill Cornell Medicine, Weill Cornell Medicine/New York Presbyterian Hospital, Professor of Medicine, Director of the Clinical and Translational Leukemia Program, Weill Medical College of Cornell University, Weill Cornell Medical College and New York Presbyterian Hospital, Weill Cornell Medicine and The New York Presbyterian Hospital, Weill Cornell Medicine and The New York Presbyterian Hospital in New York City

    Amer M. Zeidan, MD
    Yale School of Medicine and Yale Cancer Center, Yale School of Medicine and Yale Cancer Center, Yale University, Yale University and Yale Cancer Center, Yale University and Yale Comperehensive Cancer Center, Yale University School of Medicine, Department of Internal Medicine, Section of Medical Oncology and Hematology, Yale University School of Medicine and Yale Comprehensive Cancer Center,, Yale Cancer Center, Yale Comprehensive Cancer Center, Yale School of Medicine, Yale University, Yale School of Medicine: Yale Cancer Center, Yale University, Yale School of Medicine, Yale School of Medicine - Yale Cancer Center, Yale, Yale University and Yale Comprehensive Cancer Center

    Contact:

    Elijah Anseaume, Physicians’ Education Resource®, LLC (PER)
    Email: [email protected]

    Registration for In-Person Program

    Registration for Virtual Program

    Rare Clinical Spotlight: Exploring Castleman Disease, Cold Agglutinin Disease, and Acute Intermittent Porphyria

    This program is supported by Recordati Rare Diseases.


    11:00 a.m. - 2:00 p.m. Eastern time
    Hyatt - Plaza Int'l HIJK

    This session will be live streamed on hematology.org and the ASH Virtual Meeting Platform during the scheduled time.

    Join us for this unique 90-minute symposium which will showcase three rare hematologic diseases, Castleman disease (CD), cold agglutinin disease (CAD), and acute intermittent porphyria (AIP), with the shared expertise of 6 faculty that treat these rare diseases! Faculty for each disease area, will present compelling cases with interactive polling questions as a platform to weave in clinical decision-making points for improving patient outcomes. Learn what drives these diseases by understanding their pathophysiology and subsequently how to recognize signs and symptoms to properly diagnose these rare patients. Current and emerging treatment options will be presented, and faculty will disseminate key efficacy and safety data to help you understand how to choose optimal treatment approaches for patients. Take advantage of this opportunity to engage with and ask these expert faculty your important questions and walk away with more knowledge for treating patients with these diseases.

    Speakers:

    Catherine Broome, MD
    Medstar Georgetown University, Lombardi Cancer Center, Division of Hematology, MedStar Georgetown University Hospital, MedStar Georgetown University, Georgetown University, MedStar Georgetown University Hospital

    Angelika Erwin
    Cleveland Clinic

    Sudipto Mukherjee, MD,PhD,MPH
    Cleveland Clinic Foundation, Cleveland Clinic Taussig Cancer Institute, Taussig Cancer Institute, Cleveland Clinic, Cleveland Clinical, Case Comprehensive Cancer Center, Cleveland Clinic, Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Taussig Cancer Center, Cleveland Clinic, Taussig Cancer Institute, Cleveland Clinic Foundation

    Ariela Noy, MD
    Memorial Sloan-Kettering Cancer Center, memorial Sloan Kettering, Weill Cornell Medical College, Memorial Sloan Kettering Cancer Center

    Bruce Wang
    University of California, San Francisco

    Ilene Weitz, MD
    Norris Cancer Center, University of Southern California, USC Norris Cancer Center, Keck-USC School of Medicine, Keck School of Medicine of USC

    Contact:

    Carolyn Ciaramella, MedscapeLIVE
    Email: [email protected]

    Registration for In-Person Program

    Registration for Virtual Program

    Tailoring Bispecific Antibodies to Individualize R/R Follicular Lymphoma Care: A Case-Based Discussion

    This program is supported by Genmab US, Inc. and AbbVie.


    11:00 a.m. - 2:00 p.m. Eastern time
    OCCC - W311EFGH

    This session will be live streamed on hematology.org and the ASH Virtual Meeting Platform during the scheduled time.

    This 90-minute symposium will feature 2 expert hematologists/oncologists and a patient advocate from the Lymphoma Coalition as they explore the evolving role of bispecific antibodies in treating refractory/relapsed follicular lymphoma (R/R FL). Through engaging case discussions and expert presentations, you will gain insights into treatment selection, adverse event management, and overcoming logistical challenges. Learn best practices for integrating these innovative agents into patient care while emphasizing the importance of patient-centered strategies.

    Chair:

    Matthew A. Lunning, DO
    Fred and Pamela Buffett Cancer Center at the University of Nebraska Medical Center, University of Nebraska, University of Nebraska Medical Center

    Speakers:

    Natacha Bolanos
    Lymphoma Coalition

    Chan Cheah, MD
    Sir Charles Gairdner Hospital, 34 Ruislip Street, University of Western Australia, Linear Clinical Research, Sir Charles Gairdner Hospital and University of Western Australia, Sir Charles Gairdner Hospital and the University of Western Australia, Breakthrough Haematology, Department of Haematology, Sir Charles Gairdner Hospital, Linear Clinical Research, Linear Clinical Research and Sir Charles Gairdner Hospital, Linear Clinical Research and Sir Charles Gairdner Hospital, Western Australia, Medical School, University of Western Australia, Sir Charles Gairdner Hospital, Sir Charles Gairdner Hospital, Linear Clinical Research and the University of Western Australia, Sir Charles Gairdner Hospital, Pathwest Laboratory Medicine WA, Linear Clinical Research and Hollywood Private Hospital

    Contact:

    Carolyn Ciaramella, MedscapeLIVE
    Email: [email protected]

    Registration for In-Person Program

    Registration for Virtual Program

    Targeted Therapies in R/R PCNSL: New Frontiers in Treatment and Management

    This program is supported by Deciphera, a member of ONO Pharma.


    11:00 a.m. - 2:00 p.m. Eastern time
    Hyatt - Plaza Int'l DEFG

    This session will be live streamed on hematology.org and the ASH Virtual Meeting Platform during the scheduled time.

    Do you know the latest advancements in primary central nervous system lymphoma (PCNSL)? Join expert faculty in the field of PCNSL for an in-depth look at relapsed/refractory (R/R) disease. This program will review the latest clinical trial data and novel therapeutic strategies. A unique Expert Voices discussion will highlight the clinical implications of these advancements for the evolving management of R/R PCNSL.

    Chair:

    Christopher DeAngelo
    University of Nebraska Medical Center

    Speakers:

    Ayushi Chauhan, MD
    MD Anderson Cancer Center, The University of Texas at MD Anderson Cancer Center, University of Texas MD Anderson, Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, University of Texas MD Anderson Cancer Center, The University of Texas MD Anderson Cancer Center

    Ashley Sumrall
    Atrium Health

    Contact:

    Carolyn Ciaramella, MedscapeLIVE
    Email: [email protected]

    Registration for In-Person Program

    Registration for Virtual Program

    The Growing Role of CAR T-Cell Therapy in Multiple Myeloma: New Data on Earlier Lines of Therapy, Expanding Access to Treatment

    This program is supported by educational grants from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Bristol Myers Squibb, Kite Pharma, Inc., Arcellx, Inc., and Legend Biotech.


    11:00 a.m. - 2:00 p.m. Eastern time
    OCCC - W230

    This session is in-person and does not have a virtual component. Please contact the Managing Company Contact with questions.

    This live symposium will highlight cutting-edge clinical data and research findings associated with CAR T-cell therapy in multiple myeloma (MM). Experts will deliver in-depth analyses of the latest developments, focusing on real-world clinical implications, and attendees will learn about the most current and impactful data that will enhance their ability to use CAR T-cell therapies for MM. A series of brief patient case studies will set the stage and launch faculty presentations and panel discussions. The faculty will offer their interpretations of the data, share practical insights, and address potential challenges in applying the findings to patient care. Attendees will use mobile technology to participate in case studies, submit questions to faculty, and explore how new evidence can be translated into improved clinical outcomes. This combination of data presentation and faculty feedback contributes to deeper engagement and encourages practical application of learnings.

    Chair:

    Luciano Jose Costa, MD, PhD
    Division of Hematology and Medical Oncology, University of Alabama at Birmingham, Division of Hematology and Oncology, University of Alabama at Birmingham, University of Alabama at Birmingham, The University of Alabama at Birmingham, University of Alabama

    Speakers:

    Michael R. Bishop, MD
    The David and Etta Jonas Center for Cellular Therapy, University of Chicago, The David and Etta Jonas Center for Cellular Therapy University of Chicago Medicine

    Binod Dhakal, MD, MS
    Medical College of Wisconsin

    Contact:

    Kim DiGuiseppe, Haymarket Medical Education
    Email: [email protected]

    Registration for In-Person Program

  • 3

    Late Afternoon Symposia

    3:00 p.m. - 6:00 p.m.
    Eastern time

    Achieving Comprehensive Care for Chronic Immune Thrombocytopenia: Exploring Emerging Therapies to Address Patient-centric Hematological and Non-Hematological Outcomes

    This program is supported by an educational grant from Sanofi. This activity is jointly provided by AKH Inc., Advancing Knowledge in Healthcare and Catalyst Medical Education, LLC.


    3:00 p.m. - 6:00 p.m. Eastern time
    Hyatt - Regency Ballroom R

    This session is in-person and does not have a virtual component. Please contact the Managing Company Contact with questions.

    Up to 20% of pediatric patients and up to 70% of adult patients with immune thrombocytopenia have chronic disease, persisting for at least 12 months. Though available treatment options have seen some success, they are limited in their ability to address the underlying autoimmune platelet destruction etiology of ITP and often possess negative risk profiles. As a result, patients often live with uncontrolled hematological and non-hematological disease burden, including fatigue and cognitive impairment. Emerging therapies, such as Bruton’s tyrosine kinase inhibitors (BTKi), FcRN blockers, and other strategies, may offer more effective, durable, and safer treatment options to address the multi-faceted burden of ITP. Ensuring patients can access these novel therapies requires efforts to remain up-to-date with their supporting scientific data and understand principles for integrating treatments into practice. Through a dynamic format that integrates evidence-based presentations, panel discussions, and clinical cases, expert faculty participating in this symposium will bring evolving science to life and provide clinical insights to evolving strategies to address hematological and non-hematological ITP manifestations and improve the patient experience.

    Learning objectives:

    o   Recognize unmet hematological, quality of life, and long-term health needs of individual living with chronic ITP 

    o   Evaluate the MoA and clinical data on BTKi treatments, and other novel disease-targeting treatments, for chronic ITP, considering hematological, safety, and patient-reported outcomes 

    o   Propose practical strategies that support improved screening and assessment for fatigue, cognitive impairment, and other health related QoL outcomes in chronic ITP 

    o   Integrate patient-centered strategies into chronic ITP management plans that foster early intervention to address uncontrolled disease, considering current and emerging therapy options, and support shared decision-making in the second-line treatment setting

    Chair:

    David Kuter, MD, DPhil
    Massachusetts General Hospital, Harvard Medical School, Harvard Medical School, Division of Hematology Oncology, Massachusetts General Hospital, Massachusetts General Hospital, MGH Cancer Center, Massachusetts General Hospital, Harvard Medical School

    Speakers:

    Nicola Cooper, MD, FRCP, FRCPath, MA
    Imperial College Healthcare NHS Trust, Centre for Haematology, Department of Immunology and Inflammation, Imperial College London, Imperial College London, Hammersmith Hospital, Hammersmith Hospital, Imperial, Imperial College, Imperial College Healthcare; NHS Trust

    Cindy Neunert, MD
    Columbia University Irving Medical Center, Morgan Stanley Children’s Hospital; Columbia University Irving Medical Center

    Contact:

    Margaret Catherine Walker, Catalyst Medical Education
    Email: [email protected]

    Registration for In-Person Program

    Acute Hepatic Porphyria: Bridging Gaps for Better Diagnosis and Management

    This program is supported by Alnylam U.S., Inc.


    3:00 p.m. - 6:00 p.m. Eastern time
    Hyatt - Plaza Int'l HIJK

    This session will be live streamed on hematology.org and the ASH Virtual Meeting Platform during the scheduled time.

    Acute hepatic porphyria (AHP) is a rare, debilitating disease with significant diagnostic and management challenges, making provider education critical. This symposium will feature 3 expert faculty in a dynamic “Learn, Discuss, Ask” format designed to maximize engagement and knowledge exchange. Each segment begins with a focused presentation, followed by a case-based panel discussion, and concludes with audience Q&A. Participants will gain a deeper understanding of AHP, from disease awareness and diagnostic challenges to evolving management strategies and real-world applications in care. Faculty will explore the etiology, pathophysiology, clinical presentations, and unmet needs associated with AHP, while also reviewing therapeutic advances and treatment mechanisms, monitoring approaches and safety considerations, as well as future directions, including clinical trial data.

    Chair:

    Brendan Mcguire
    University of Alabama at Birmingham

    Speakers:

    Rebecca Karp
    Massachusetts General Hospital

    Akshata Moghe
    University of Texas Health Science Center at Houston, University of Texas Health Science Center

    Contact:

    Carolyn Ciaramella, MedscapeLIVE
    Email: [email protected]

    Registration for In-Person Program

    Registration for Virtual Program

    Bridging the Gaps in CAR T-Cell Therapy for Hematological Malignancies: Expert Guidance, Clinical Experience and Increased Access

    This program is supported by Roswell Park Alliance Foundation and Bristol Myers Squibb.


    3:00 p.m. - 6:00 p.m. Eastern time
    OCCC - W230

    This session is in-person and does not have a virtual component. Please contact the Managing Company Contact with questions.

    Chimeric antigen receptor (CAR) T cell therapy has reshaped the treatment landscape for B-cell malignancies, yet major clinical and implementation challenges persist.

    This symposium addresses critical unmet needs in the field:

    • Optimizing CAR T cells in real-world practice
    • Sequencing therapies
    • Managing post-relapse scenarios
    • Understanding resistance biology
    • Expanding access to underserved populations

    Given the rapid evolution of therapies and shifting treatment paradigms, there is an urgent need to equip clinicians and researchers with expert guidance on how to navigate these complex decisions and translate new data into patient-centered care.

    Chairs:

    Marco Davila, MD, PhD
    Roswell Park Comprehensive Cancer Center, Roswell Park Comprehensive Cancer

    Renier Brentjens
    Deputy Director, Chair, Department of Medicine, Roswell Park Comprehensive Cancer Center

    Speakers:

    Julio C Chavez, MD, MS
    H Lee Moffitt Cancer Center, Sr. Associate Consultant, Lymphoma Program Lead, Mayo Clinic, H. Lee Moffitt Cancer and Research Institute, H. Lee Moffitt Cancer Center & Research Institute, H.Lee Moffitt Cancer Center, Moffit Cancer Center, Department of Malignant Hematology, Moffitt Cancer Center, H. Lee Moffitt Cancer Center, Moffitt Cancer Center

    Marco Davila, MD, PhD
    Roswell Park Comprehensive Cancer Center, Roswell Park Comprehensive Cancer

    Francisco Hernandez-Ilizaliturri, MD
    Roswell Park Comprehensive Cancer Center, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Roswell Park, Roswell Park Comprehensive Cancer Center, Director of Lymphoma Research and Lymphoma Translational Research Lab, Roswell Park Comprehensive Cancer Center

    Shernan Holtan, MD
    Chief, Blood and Marrow Transplantation Section, Roswell Park Comprehensive Cancer Center, Roswell Park Comprehensive Cancer Center

    Frederick Locke, MD
    H Lee Moffitt Cancer Center, H. Lee Moffitt Cancer Center and Research Institute, Lee Moffitt Cancer Center, H. Lee Moffitt Cancer and Research Institute, H. Lee Moffitt Cancer Center & Research Institute, Moffit Cancer Center, Chair, Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, H. Lee Moffitt Cancer Center, Moffitt Cancer Center

    Contact:

    Ashley Snowden, Roswell Park Comprehensive Cancer Center
    Email: [email protected]

    Registration for In-Person Program

    BRINGING EMERGING TREATMENTS TO ALL PATIENTS: Strategies for Implementing T-cell Redirection Therapies in Community Oncology Practices

    This program is supported by Amgen, Pfizer Oncology and Indy Hematology Education Inc.


    3:00 p.m. - 6:00 p.m. Eastern time
    OCCC - Valencia Room W415BC

    This session will be live streamed on hematology.org and the ASH Virtual Meeting Platform during the scheduled time.

    Innovative immune effector therapies, including CAR T-cell and bi-specific antibody treatments, have transformed cancer care but remain largely inaccessible to community oncology practices. This symposium is dedicated to bridging this gap by establishing the necessary infrastructure, protocols, and training to safely and effectively administer these lifesaving therapies in community settings. By promoting equitable access, fostering clinical trial participation, and supporting diverse patient populations, we aim to reduce disparities and expand the reach of modern cellular therapies.

    Chair:

    Ruemu Ejedafeta Birhiray, MD
    Hematology Oncology of Indiana, Marian University: Wood College of Osteopathic Medicine, Hematology Oncology of Indiana/American Oncology Network, Indy Hematology Education Inc, Indy Hematology Education Inc.

    Speakers:

    Ralph Vincent Boccia, MD
    The Center for Cancer and Blood Disorders, Center for Cancer and Blood Disorders

    Tara Graff, DO,MS
    Mission Cancer and Blood

    Nikhil Munshi, MD
    Dana-Farber Cancer Institute, Harvard Medical School, Jerome Lipper Multiple Myeloma Disease Center, Dana-Farber Cancer Institute, Harvard Medical School. VA Boston Healthcare System, Boston, MA., The Jerome Lipper Multiple Myeloma Center,Dana-Farber Cancer Institute, Harvard Medical School, VA Boston Healthcare System, Boston Veterans Administration Healthcare System, Brigham and Women's Hospital, Brigham and Women’s Hospital, Dana Farber Cancer Institute, Dana-Farber Cancer Insitute, Dana-Farber Cancer Institute, Veterans Administration Boston Healthcare System, Dana Farber Cancer Institute, Harvard Medical School, Harvard Medical School

    Tycel Phillips, MD, FASCO
    Associate Professor, Division of Lymphoma, Department of Hematology and Hematopoietic Cell Transplantation; City of Hope Comprehensive Cancer Center, City of Hope, University of Michigan Comprehensive Cancer Center (Present Affiliation: City of Hope, Duarte, CA, United States), University of Michigan Comprehensive Cancer Center (present affiliation: City of Hope, Duarte, CA, USA), City of Hope Comprehensive Cancer Center, City of Hope National Medical Center

    Richard Stone, MD
    Dana-Farber Cancer Center, Dana-Farber Cancer Institute, Dana-Farber/Partners CancerCare, Dana Farber Cancer Institute, Dana-Farber Cancer Institute, Harvard Medical School

    Contact:

    Sam Ranger, Indy Hematology Education Inc., Indy Hematology Education Inc
    Email: [email protected]

    Registration for In-Person Program

    Registration for Virtual Program

    Cases and Conversations™: Optimizing Patient Outcomes in Pediatric/AYA and Adult ALL/LBL With Asparaginase Therapies and Combinations

    This program is supported by Servier Pharmaceuticals LLC.


    3:00 p.m. - 6:00 p.m. Eastern time
    OCCC - Tangerine Ballroom F1

    This session will be live streamed on hematology.org during the scheduled time.

    The live portion of this curriculum will be presented as a 2.5-hour Friday Satellite Symposium (FSS) held prior to the 2025 ASH Annual Meeting.

    This satellite program will bring together four clinical experts to review the latest data regarding the management of CML, with short didactic lectures supplemented by panel discussions of pertinent clinical challenges, emerging treatment strategies, and real-world applications of current guidelines.

    To further enhance the integration of recent data into practice, the program will feature an interactive question-and-answer session between the faculty and attendees to emphasize areas of educational need, highlight areas of debate, and illustrate the application of new data in defined clinical situations.

    Chairs:

    Daniel J Deangelo, MD, PhD
    Dana-Farber Cancer Institute, Dana Farber Cancer Institute, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Dana-Farber/Partners CancerCare, Department of Medical Oncology, Dana-Farber Cancer Institute

    Daniel J Deangelo, MD, PhD
    Dana-Farber Cancer Institute, Dana Farber Cancer Institute, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Dana-Farber/Partners CancerCare, Department of Medical Oncology, Dana-Farber Cancer Institute

    Speakers:

    Shira Dinner, MD
    Feinberg School of Medicine and the Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Northwestern Memorial Hospital, Alliance for Clinical Trials in Oncology, Northwestern University

    Stephen P. Hunger, MD
    Children’s Hospital of Philadelphia, Children's Hospital of Philadelphia, University of Pennsylvania, University of Pennsylvania, Perelman School of Medicine

    Jae Park, MD
    Cellular Therapy Service, Memorial Sloan Kettering Cancer Center, MSKCC, Memorial Sloan Kettering, Department of Medicine, Weill Cornell Medical College, Memorial Sloan Kettering Cancer Center

    Contact:

    Elijah Anseaume, Physicians’ Education Resource®, LLC (PER)
    Email: [email protected]

    Registration for In-Person Program

    Registration for Virtual Program

    Cracking the Code: Menin Inhibitors and the Next Frontier in AML Treatment

    This program is supported by PRIME Education. There is no fee to participate. This activity is supported by an educational grant from Kura and Syndax.


    3:00 p.m. - 6:00 p.m. Eastern time
    OCCC - W331

    This session will be live streamed on hematology.org during the scheduled time.

    Join acute myeloid leukemia (AML) experts as they take a deep dive into the latest evidence from clinical trials for new and emerging menin inhibitors for AML. Specifically, faculty will guide the audience through various menin inhibitor topics, including (1) the biologic rationale and implications of KMT2A rearrangements and NPM1 mutations for AML prognosis, (2) clinical evidence supporting guideline recommendations for menin inhibitors in AML treatment plans and the potential place in therapy for emerging agents, (3) nuances of treatment strategy including relation to transplant, dosing and administration, (4) appropriate genetic tests and the implications on treatment decision-making, and (5) mitigation, monitoring and managing unique adverse events of menin inhibitor therapies. Additionally, throughout the program, faculty will engage the onsite and virtual attendees through gamified interactive polling and participate in a live Q&A. Furthermore, to support faculty in synthesizing the latest data, an AML Clinical Trial Pocket Guide will be available providing a concise overview of novel menin inhibitors and combinations in clinical trials. Altogether, this satellite symposium will feature expert discussion and case-based learning designed to decode the latest clinical evidence on menin inhibitors to optimize treatment of patients with R/R AML.

    Chair:

    Joshua Zeidner, MD
    Lineberger Comprehensive Cancer Center, University of North Carolina School of Medicine, University of North Carolina School of Medicine, Lineberger Comprehensive Cancer Center, University of North Carolina, UNC Lineberger Comprehensive Cancer Center, University of North Carolina, University of North Carolina Lineberger Comprehensive Cancer Center, University of North Carolina, Lineberger Comprehensive Cancer Center, Lineberger Comprehensive Cancer Center

    Speaker:

    Justin Watts, MD
    Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, University of Miami Sylvester Comprehensive Cancer Center, University of Miami, Sylvester Comprehensive Cancer Center, University of Miami, University of Miami Miller School of Medicine, University of Miami/Sylvester Comprehensive Cancer Center (SCCC)

    Contact:

    Eryn Litvinas, PRIME Education
    Email: [email protected]

    Registration for In-Person Program

    Registration for Virtual Program

    Expert Second Opinion: Investigators Discuss the Optimal Management of Patients with Myelofibrosis and Systemic Mastocytosis

    This program is supported by educational grants from Blueprint Medicines, Bristol Myers Squibb, GSK, and Incyte Corporation.


    3:00 p.m. - 6:00 p.m. Eastern time
    Hyatt - Regency TUV

    This session will be live streamed on hematology.org during the scheduled time.

    This 2-hour CME-accredited activity – offered to both in-person and virtual attendees – will focus on the management of patients with myelofibrosis (MF) and systemic mastocytosis (SM). 5 clinical investigators will serve as the faculty and Dr Neil Love, RTP president, will moderate. Prior to the meeting, Research To Practice (RTP) will record interviews with 3 additional investigators who will present interesting teaching cases from their practices of patients with MF. To begin each of the 5 meeting modules, excerpts from the recorded case interviews will be broadcast. The panelists will then discuss the optimal management of the patients presented. Each faculty member will then deliver a formal presentation reviewing available research. Attendees will be able to submit questions and cases of their own, a number of which will be incorporated into the discussion. Pre-registration is advised as seating is limited.

    Chair:

    Neil Love, MD
    Research To Practice

    Speakers:

    Claire Harrison, DM
    Guy’s and St Thomas’ NHS Foundation Trust, Guy's and St Thomas' National Health Service Foundation Trust, Guy's and St Thomas' NHS Foundation Trust, Department of Haematology, Guy’s and St Thomas’ NHS Foundation Trust, London, United Kingdom

    Andrew T Kuykendall, MD
    Moffitt Cancer Center, Tampa, FL, H Lee Moffitt Cancer Center, H. Lee Moffitt Cancer Center, H. Lee Moffitt Cancer Center & Research Institute, Moffitt Cancer Center, H Lee Moffitt Cancer Center and Research Institute, H. Lee Moffitt Cancer and Research Institute, H. Lee Moffitt Cancer Center and Research Institute

    Stephen Oh, MD, PhD
    Division of Hematology, Washington University School of Medicine, Siteman Cancer Center, Washington University School of Medicine, Washington University School of Medicine in St. Louis, St. Louis, Washington University School of Medicine, St. Louis, Washington University, Washington University in St. Louis School of Medicine - Siteman Cancer Center, Washington University School of Medicine in St. Louis

    Jeanne Palmer
    Mayo Clinic, Mayo Clinic College of Medicine and Science, Mayo Clinic Arizona, Vice Chair, and Section Chief for Hematology, Program Director for the Blood and Marrow Transplant Program, Mayo Clinic

    Raajit Rampal, MD, PhD
    Department of Medicine, Leukemia Service, Memorial Sloan Kettering Cancer Center, Department of Medicine, Leukemia Service, Memorial Sloan-Kettering Cancer Center, New York, NY, USA, Memorial Sloan Kettering Cancer Center, Memorial Sloan Kettering Cancer Center,, Memorial Sloane Kettering Cancer Center

    Contact:

    Sylvia Eriksen, Research To Practice
    Email: [email protected]

    Registration for In-Person Program

    Registration for Virtual Program

    Filling in the Gaps in Hemophilia Guideline Recommendations: Evidence-Based Strategies to Optimize Patient-Relevant Outcomes

    This program is supported by an independent medical education grant from Sanofi.


    3:00 p.m. - 6:00 p.m. Eastern time
    OCCC - Valencia Room W415A

    This session is in-person and does not have a virtual component. Please contact the Managing Company Contact with questions.

    Emerging therapies have the potential to transform care for patients with hemophilia, a rare chronic bleeding disorder in which impaired coagulation leads to spontaneous and traumatic bleeding. This CME-approved live panel discussion will help clinicians frame recent hemophilia guidelines into clinical practice and provide recommendations on the use of new therapies in hemophilia patients of all ages. Case studies will be used to review recent clinical trial data and examine the pros and cons of treatment options, including novel clotting factor concentrates, factor VIII mimetics, rebalancing agents, and gene therapies. Hemophilia panel members will use polling to engage the audience in a discussion of how to manage hemophilia A and B through shared decision making at all stages of their patients’ lives.

    Chairs:

    Allison Wheeler, MD, MSCI
    Scientific Director, Washington Center for Bleeding Disorders, University of Washington School of Medicine, University of Washington School of Medicine, University of Washington

    Lynn Malec, MD, MSc
    Versiti Blood Research Institute, Division of Hematology & Oncology, Departments of Medicine and Pediatrics, Medical College of Wisconsin, Versiti, Blood Research Institute

    Speakers:

    Shannon L. Meeks, MD
    Professor of Pediatrics, Aflac Cancer and Blood Disorders Center, Emory University

    Michael Recht
    Yale University, Yale Center for Bleeding and Clotting Disorders, Yale School of Medicine, National Bleeding Disorders Foundation, Yale School of Medicine

    Annette von Drygalski
    University of California San Diego Health, Director, Center for Bleeding and Clotting Disorders, University of California, San Diego, University of California, San Diego

    Contact:

    Madelyne Fabrizio, i3 Health
    Email: [email protected]

    Registration for In-Person Program

    Medical Crossfire®: Navigating GVHD Prophylaxis, Acute and Chronic Care - Targeted Strategies to Elevate Patient Outcomes

    This program is supported by Orca Bio.


    3:00 p.m. - 6:00 p.m. Eastern time
    OCCC - Tangerine Ballroom F2

    This session will be live streamed on hematology.org during the scheduled time.

    This program convenes a panel of world-renowned expert faculty in GVHD to tackle pressing clinical issues. The panel offers participants invaluable clinical pearls, practical strategies, and insights from leaders in the field. The dynamic format encourages active engagement, challenging participants to critically evaluate their practices and apply the latest evidence to improve patient care.

    Chair:

    Corey Cutler, MD,FRCPC,MPH
    Dana Farber Cancer Institute, Dana-Farber Cancer Institute, Harvard Medical School

    Speakers:

    Amin Alousi, MD
    MD Anderson Cancer Center, The University of Texas MD Anderson Cancer Center, MD Anderson, University of Texas MD Anderson Cancer Center

    Mehdi Hamadani, MD
    CIBMTR/Medical College of Wisconsin, The Mikael?Rayaan?Foundation Global Research Training Institute (MRF GRTI), Medical College of Wisconsin, Medical College of Wisconsin Cancer Center, CIBMTR® (Center for International Blood and Marrow Transplant Research), Medical College of Wisconsin, Medical College of Wisconsin,?Milwaukee, WI

    Anna Sureda Balarí, MD,PhD
    Hematology Department, Institut Català d'Oncologia - Hospitalet, IDIBELL, University of Barcelona, Institut Català d'Oncologia - L'Hospitalet, Institut de Ciències Biomèdiques de Bellvitge (IDIBELL), Universitat de Barcelona, Hospital Duran i Reynals, Institut d’Investigacio Biomedica de Bellvitge (IDIBELL), Universitat de Barcelona, Institut Catala d'Oncologia - Hospital Duran i Reynals, Barcelona, Spain, Institut Català d'Oncologia - Hospital Duran i Reynals, L’Hospitalet del LLobregat, Clinical Hematology Department, Institut Català d'Oncologia - L'Hospitalet, Institut de Ciències Biomèdiques de Bellvitge (IDIBELL), Universitat de Barcelona, Clinical Hematology Department, Institut Català d’Oncologia – L’Hospitalet, IDIBELL, Universitat de Barcelona, Hematology Department, Institut Català d'Oncologia (ICO), Hematology Department, Institut Català d’Oncologia, Barcelona-L’Hospitalet, IDIBELL, Universitat de Barcelona, Institut Català D'Oncologia L'Hospitalet, Clinical Hematology Department, Institutr Català d'Oncologia - L'Hospitalet, Institut de Ciències Biomèdiques de Bellvitge (IDIBELL), Universitat de Barcelona, Grupo Español de Trasplante de Progenitores Hematopoyéticos y Terapia Celular, Hematology Department, Institut Català d’Oncologia-L’Hospitalet, IDIBELL, Universitat de Barcelona, Barcelona, Spain, Hospital Duran i Reynals, ICO-Hospitalet, Institut d'Investigació Biomèdica de Bellvitge, Institut Català d'Oncologia - Hospital Duran i Reynals, Institut Català d'Oncologia - Hospital Duran i Reynals, Institut Català d'Oncologia-L'Hospitalet, Instituto de Investigación Biomédica de Bellvitge, Universitat de Barcelona, Institut Catala d’Oncologia Institut Josep Carreras, Institut Català d’Oncologia-Hospitalet, IDIBELL

    Contact:

    Elijah Anseaume, Physicians’ Education Resource®, LLC (PER)
    Email: [email protected]

    Registration for In-Person Program

    Registration for Virtual Program

    Myeloma Myth Busters: Investigating the Now, Soon, and Future Clinical Implications of CELMoDs

    This program is supported by Bristol Myers Squibb. Provided by Clinical Care Options, LLC.


    3:00 p.m. - 6:00 p.m. Eastern time
    Hyatt - Regency Ballroom OPQ

    This session will be live streamed on hematology.org during the scheduled time.

    Join CCO for an interactive, case-based symposium exploring the evolving role of CELMoD therapy in multiple myeloma (MM). Through a unique “Two Truths and a Myth” gameshow format, expert faculty will unpack key mechanistic differences between CELMoDs and IMiDs, review pivotal trial data for iberdomide and mezigdomide, and discuss the clinical implications of MRD-negative complete response as a surrogate endpoint. Participate in dynamic faculty Q&A sessions and real-world patient case challenges that highlight how CELMoDs may be integrated into near-future treatment paradigms and clinical trials. Prepare for the next wave of innovation in MM care.

    Chair:

    Niels W.C.J. Van De Donk
    Amsterdam University Medical Center, Department of Hematology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam University Medical Center, Vrije Universiteit Amsterdam

    Speakers:

    Jesús Berdeja, MD
    Greco-Hainsworth Centers for Research at Tennessee Oncology, Sarah Cannon Research Institute, Tennessee Oncology, The Greco-Hainsworth Tennessee Oncology Centers for Research, Sarah Cannon Research Institute at Tennessee Oncology, Tennessee Oncology, Nashville, GHCR Tennessee Oncology, Greco-Hainsworth Centers for Research

    Amrita Krishnan, MD
    City of Hope, City of Hope National Medical Center, City of Hope Orange County, City of Hope Comprehensive Cancer Center, City of Hope Cancer Center

    Contact:

    Ishana Fleurant, Clinical Care Options, LLC.
    Email: [email protected]

    Registration for In-Person Program

    Registration for Virtual Program

    PER® Tumor Board: Charting a New Course in the Treatment of Newly Diagnosed Multiple Myeloma

    This program is supported by Sanofi.


    3:00 p.m. - 6:00 p.m. Eastern time
    OCCC - Tangerine Ballroom F3-4

    This session will be live streamed on hematology.org during the scheduled time.

    This satellite program will bring together four clinical experts to review real-world cases that synthesize recent data from landmark trials of new approaches for the management of NDMM into practical insights for clinicians to implement in routine practice. To further enhance the integration of recent data into practice, the program will feature an interactive question-and-answer session between the faculty and attendees to emphasize areas of educational need, highlight areas of debate, and illustrate the application of new data in defined clinical situations.

    Chair:

    Ajai Chari, MD
    University of California, San Francisco, University of California San Francisco

    Speakers:

    María-Victoria Mateos, MD, PhD
    Hospital Universitario de Salamanca, Instituto de Investigación Biomédica de Salamanca, Instituto de Biología Molecular y Celular del Cáncer (Universidad de Salamanca-Consejo Superior de Investigaciones Científicas), CIBERONC, University Hospital of Salamanca/IBSAL/Cancer Research Center-IBMCC (USAL-CSIC), University Hospital Salamanca/ISAL, Complejo Asistencial Universitario de Salamanca/IBSAL/CIC/CIBERONC, Hematology Department, University Hospital of Salamanca, IBSAL. Cancer Research Center-IBMCC (USAL-CSIC)., Hospital Universitario de Salamanca Hematología. Instituto de investigación biomédica de Salamanca (IBSAL), CIBER-ONC number CB16/12/00233, Salamanca, Spain, Hospital Universitario de Salamanca, Instituto de Investigacion Biomedica de Salamanca (IBSAL), Salamanca, Spain, Hospital Universitario de Salamanca, Instituto de Investigacion Biomedica de Salamanca (IBSAL), University of Salamanca, Hospital Universitario de Salamanca-IBSAL, CIBERONC and Centro de Investigación del Cáncer, IBMCC (USAL-CSIC), University Hospital of Salamanca, IBSAL, and Cancer Research Center, IBMCC, University Hospital of Salamanca/IBSAL/CIC/CIBERONC, GEM, Fundacion PETHEMA, Hematology Department, University Hospital of Salamanca/IBSAL/Cancer Research Center-IBMCC (USAL-CSIC), Hospital Universitario de Salamanca, Instituto de Investigación Biomédica de Salamanca (IBSAL), Centro de Investigación del Cáncer (IBMCC-USAL, CSIC), Hospital Universitario de Salamanca, Instituto de Investigacion Biomedica de Salamanca, University of Salamanca, Hospital Universitario de Salamanca-Instituto Biosanitario de Salamanca, Hospital Universitario de Salamanca/IBSAL/CIC/Ciberonc, University Hospital of Salamanca, University of Salamanca, Hematology Department, Hospital Universitario de Salamanca, Instituto de investigacion Biomedica de Salamanca (IBSAL), Hospital Universitario de Salamanca, Hospital Universitario Salamanca

    Mohamad Mohty, MD, PhD
    APHP, EBMT Paris Study Unit, Hôpital Saint Antoine, Hopital Saint Antoine, Sorbonne Université, Hôpital Saint-Antoine, AP-HP, Sorbonne University, Saint-Antoine Hospital, AP-HP, Sorbonne University, Saint-Antoine Hospital, AP-HP, INSERM UMRs 938, 18. Department of Clinical Hematology and Cellular Therapy, Saint-Antoine Hospital, AP-HP, Sorbonne University, INSERM, Saint-Antoine Research Centre, EBMT Paris study office, Sorbonne University, Department of Haematology, Saint Antoine Hospital; INSERM UMR 938, EBMT Paris Study Unit, Sorbonne University, Department of Haematology, Saint Antoine Hospital; INSERM UMR 938, Hôpital Saint-Antoine, Sorbonne Université, AP-HP,, Sorbonne University, Department of Haematology, Saint Antoine Hospital; INSERM UMR 938, Sorbonne University, Saint-Antoine Hospital, INSERM UMRs 938, Department of Clinical Hematology and Cellular Therapy, Saint-Antoine Hospital, AP-HP, Sorbonne University, INSERM, Saint-Antoine Research Centre, Department of Hematology and Cell Therapy, Hôpital Saint-Antoine APHP, Sorbonne University, EBMT Paris Office, Hôpital Saint Antoine, Hôpital Saint Antoine, APHP, Saint-Antoine Hospital Sorbonne University, Centre de Recherche Saint-Antoine, EBMT Paris Office, Hôpital Saint Antoine, Paris, France, INSERM UMRs 938, Sorbonne University, Saint-Antoine Hôpital (AP-HP), Université Sorbonne

    Contact:

    Elijah Anseaume, Physicians’ Education Resource®, LLC (PER)
    Email: [email protected]

    Registration for In-Person Program

    Registration for Virtual Program

    Personalizing Relapsed/Refractory DLBCL With Bispecific Antibody Therapy: A Case-Based Discussion

    This program is supported by Genmab US, Inc. and AbbVie.


    3:00 p.m. - 6:00 p.m. Eastern time
    OCCC - W311EFGH

    This session will be live streamed on hematology.org and the ASH Virtual Meeting Platform during the scheduled time.

    This unique interactive program is designed to enhance your clinical approach to refractory/relapsed diffuse large B-cell lymphoma (R/R DLBCL). Our expert faculty, including a patient advocate from the Lymphoma Coalition, will utilize real-world case studies to highlight best practices in personalizing DLBCL care with bispecific antibodies. Stay updated on advancements in R/R DLBCL treatment.

    Chair:

    Joshua Brody, MD
    Icahn School of Medicine at Mount Sinai

    Speakers:

    Elizabeth Brem, MD
    UC Irvine, University of Califorina Irvine, University of California, Irvine, UCI Health

    Lorna Warwick, BA
    Lymphoma Coalition

    Contact:

    Carolyn Ciaramella, MedscapeLIVE
    Email: [email protected]

    Registration for In-Person Program

    Registration for Virtual Program

    Staying in the Lead: Navigating the Changing Course of Sickle Cell Disease Management —A CME COMPETE™: SCD Edition

    This program is supported by Novo Nordisk Inc. Provided by Integritas Communications.


    3:00 p.m. - 6:00 p.m. Eastern time
    OCCC - W224CDGH

    This session will be live streamed on hematology.org during the scheduled time.

    Sickle cell disease (SCD) presents a lifelong clinical burden with significant variability across patients. It is a leading cause of mortality, morbidity, and health disparities, yet remains considerably undertreated. Current therapeutic innovation is rapidly shifting and so must the treatment paradigm. This symposium will use a Test–Teach–Compete format to engage attendees in a high-impact learning experience focused on the evolving landscape of SCD care. Through a blend of didactic teaching, interactive case challenges, and dynamic gamification elements, expert faculty will guide participants through a progression of key topics—from foundational pathophysiology and lifelong disease burden to the limitations of traditional treatments and the promise of curative and disease-modifying options, including FDA-approved gene-editing treatments and emerging pyruvate kinase activators. Join us for an engaging, case-driven session designed to help transform how we approach the care of patients living with SCD.

    Speakers:

    Lakiea Bailey, PhD
    Director, Sickle Cell Consortium; Patient Advocate, Educator, Research Scientist, Sickle Cell Consortium

    Modupe Idowu, MD
    Director, Hematology/Oncology, UTHealth, University of Texas McGovern Medical School, UTHealth McGovern Medical School

    Nirmish Shah, MD
    Duke university, Associate Professor, Hematology, Duke University

    Contact:

    Shannon Stevenson, Integritas, Integritas Communications
    Email: [email protected]

    Registration for In-Person Program

    Registration for Virtual Program

    Visualizing Novel Pathways to Optimizing Care for Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)

    This program is supported by Novartis Pharmaceuticals.


    3:00 p.m. - 6:00 p.m. Eastern time
    OCCC - W224ABEF

    This session will be live streamed on hematology.org during the scheduled time.

    Paroxysmal nocturnal hemoglobinuria (PNH) is a rare genetic hematologic disorder that stems from deficient proteins that mediate the complement pathway. [DeZern 2015] Unregulated complement activity leads to its hallmark manifestations of hemolytic anemia, bone marrow failure, and elevated risk of thrombosis. The clinical symptoms vary considerably between affected individuals. Patients may present with unexplained hemolytic anemia, fatigue, jaundice, and red/pink/dark urine, while others experience headaches, dysphagia, scleral icterus, or confusion. Approximately 10-20 people per million worldwide live with PNH. [Cancado 2021] Although it can occur at any age, PNH is often diagnosed between the ages of 30 to 40. [Hill 2017]; [Schrezenmeier 2020].

    Before the availability of effective treatments, the median survival was just 15 to 20 years, with thrombosis as the leading cause of death. [Bektas 2020a] The development of targeted complement inhibitors has transformed outcomes for patients with PNH, enabling patients to achieve life expectancies similar to age-matched controls. [Bodo 2023]

    Speakers:

    Caroline Piatek, MD
    University of Southern California Norris Comprehensive Cancer Center, University of Southern California

    Jamile Shammo, MD, FASCP, FACP
    Northwestern University Feinberg School of Medicine

    Contact:

    Kelly McGregor, PER
    Email: [email protected]

    Registration for In-Person Program

    Registration for Virtual Program

  • 4

    Evening Symposia

    7:00 p.m. - 10:00 p.m.
    Eastern time

    EXPERT SECOND OPINION: Investigators Discuss the Role of Novel Treatment Approaches in the Care of Patients with Follicular Lymphoma and Diffuse Large B-Cell Lymphoma

    This program is supported by educational grants from ADC Therapeutics, Genentech, a member of the Roche Group, Incyte Corporation, and Pfizer Inc.


    7:00 p.m. - 10:00 p.m. Eastern time
    Hyatt - Regency TUV

    This session will be live streamed on hematology.org during the scheduled time.

    This 2-hour CME-accredited activity – offered to both in-person and virtual attendees – will focused on the integration of novel approaches into the care of patients with DLBCL and FL. 5 investigators will serve as the faculty and Dr Neil Love, RTP president, will moderate. Prior to the meeting, Research To Practice (RTP) will record interviews with 3 additional investigators who will present interesting teaching cases from their practices of patients with DLBCL or FL treated with novel agents/strategies. To begin each of the 5 meeting modules, excerpts from the recorded case interviews will be broadcast. The panelists will then discuss the optimal management of the patients presented. 1 faculty member will then deliver a formal presentation reviewing available research. Attendees will be able to submit questions and cases of their own, a number of which will be incorporated into the discussion. Pre-registration is advised as seating is limited.

    Chair:

    Neil Love, MD
    Research To Practice

    Speakers:

    Nancy L Bartlett, MD
    Siteman Cancer Center, Siteman Cancer Center, Washington University, Washington University School of Medicine, Washington University School of Medicine, Siteman Cancer Center, Siteman Cancer Center, Washington University School of Medicine, Division of Oncology, Washington University School of Medicine, Washington University

    Matthew Matasar, MD, MS
    Rutgers Cancer Institute, Rutgers University, Memorial Sloan Kettering Cancer Center, Rutgers Cancer Institute of New Jersey and RWJ Barnabas Health, Rutgers Cancer Institute of New Jersey

    Loretta J Nastoupil
    CommonSpirit Mercy Hospital, MD Anderson Cancer Center

    Grzegorz Nowakowski
    Mayo Clinic

    Pier Luigi Zinzani, MD, PhD
    Hematology-Università di Bologna S.Orsola Malpighi, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia “Seràgnoli”, IRCCS Azienda Ospedaliero–Universitaria Policlinico Sant’Orsola-Malpighi, University of Bologna, Institute of Hematology, Department of Experimental, Diagnostic and Specialty Medicine, Institute of Hematology 'Seràgnoli' University of Bologna, Department of Medical and Surgical Sciences - University of Bologna, IRCCS Azienda Ospedaliero-Universitaria di Bologna Istituto di Ematologia “Seràgnoli”, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia 'Seràgnoli', Seràgnoli; Dipartimento di Scienze Mediche e Chirurgiche, Università di Bologna, Policlinico S. Orsola-Malpighi - Bologna, Italy, Bologna University, Dipartimento di Scienze Mediche e Chirurgiche, Università di Bologna, Institute of Hematology “Seràgnoli” University of Bologna, Institute of Hematology “Seràgnoli”, University of Bologna, Institute of Hematology University of Bologna, IRCCS Azienda Ospedaliero-Universitaria di Bologna Istituto di Ematologia “Seragnoli”, University of Bologna, Institute of Hematology 'Seràgnoli,' University of Bologna, IRCCS Azienda Ospedaliero-Universitaria di Bologna, IRCCS Azienda Ospedaliero-Universitaria di Bologna??Istituto di Ematologia “Seràgnoli”?and Dipartimento di Scienze Mediche e Chirurgiche,?Università di Bologna, University of Bologna School of Medicine

    Contact:

    Sylvia Eriksen, Research To Practice
    Email: [email protected]

    Registration for In-Person Program

    Registration for Virtual Program

    Hot Topics in Myelofibrosis Management: Navigating the Latest Therapeutic Advances in Clinical Practice

    This program is supported by educational grants from <span>Geron Corporation, Karyopharm Therapeutics, Kartos Therapeutics, and Sumitomo Pharma America, Inc. This activity is provided by PRIME Education. There is no fee to participate.</span>


    7:00 p.m. - 10:00 p.m. Eastern time
    OCCC - W331

    This session will be live streamed on hematology.org during the scheduled time.

    Join myelofibrosis experts as they take a deep dive into the latest clinical evidence and practical considerations for various Hot Topics in myelofibrosis (MF) care. Bolstered by the latest clinical efficacy and safety data, educational material will focus on strategies to optimize guideline-aligned, patient-centered treatment selection, integrate evidence-based anemia management strategies into clinical practice, and synthesize the latest data on emerging therapies and their practice-changing potential. Specifically, faculty will guide the audience through various Hot Topics in the management of MF, including (1) individualizing JAK inhibitor selection, response monitoring, and sequencing, (2) assessing anemia symptoms and burden and optimizing treatment decisions to minimize transfusion requirements, (3) differentiating emerging MF therapies by MOA and clinical safety and efficacy data, and (4) understanding shifting treatment goals to achieve deeper clinical and molecular response. Additionally, throughout the program, faculty will engage the onsite and virtual attendees through gamified interactive polling and participate in a live Q&A. Altogether, this satellite symposium will feature expert discussion and case-based learning  designed to support providers master the clinical data and adopt evidence-based strategies to deliver comprehensive MF care.

    Chair:

    John O. Mascarenhas, MD
    Icahn School of Medicine at Mount Sinai, Ichan School of Medicine, Mount Sinai Hospital, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA, Division of Hematology/Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, Tisch Cancer Institute, Icahn School of Medicine, Mount Sinai Medical Center, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai

    Speaker:

    Lindsay Rein, MD
    Duke Cancer Institute, Duke University, Duke University Medical Center, Department of Medicine, Duke University School of Medicine, Duke University School of Medicine

    Contact:

    Eryn Litvinas, PRIME Education
    Email: [email protected]

    Registration for In-Person Program

    Registration for Virtual Program

67th ASH Annual Meeting and exposition

San Diego Convention Center

Registration for ASH members, non-members, groups, exhibitors, and media is now open!

View Additional Information

Explore the Annual Meeting